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Abstract 
 
 
Modern vaccine development has focused on developing effective vaccines without compromising 
vaccine safety and tolerability. This has prompted the rational design of modern subunit vaccines, 
which are safe and well-characterized, by incorporating key immunogenic elements of pathogen 
properties to induce tailored responses of appropriate strength, quality and specificity. Based on this 
strategy, Virus-like particles (VLPs) and their subunit capsomeres have been utilized as a platform 
to present a variety of foreign epitopes from targeted pathogens. Promising vaccine candidates 
based on the modular murine polyomavirus (MPyV) VLP or capsomere platform have been 
developed to target influenza A and Group A streptococcus (GAS), which are microbially-produced 
rapidly at low-cost and are easily scalable. However, the understanding of their effectiveness in 
inducing specific immune response is limited. Building on the previous successful outcomes with 
these vaccine candidates, different strategies were investigated to improve their immunogenicity 
and protective efficacy. This involved the refinement of vaccine at formulation level (e.g. 
adjuvants) or administration route (e.g. parenteral or non-parenteral). This work utilizes a 
fluorescence optical imaging approach for in vivo tracking of vaccine components after 
immunization to correlate the immune responses with their biodistribution. The main objectives of 
this thesis are: (i) demonstrating the non-carrier adjuvanting efficacy of PLGA and silica 
nanoparticles for modular capsomeres presenting influenza M2e antigen; (ii) visualizing the in vivo 
trafficking of silica nanoparticle-adjuvanted modular capsomere formulation by fluorescence 
imaging to understand their ability to induce effective antibody-biased immune response, even 
though these components are not attached prior to immunization; (iii) determining the potential of 
sublingual delivery of modular VLPs presenting GAS J8 antigen; and (iv) evaluating the in vivo 
trafficking of sublingually-administered modular VLPs to comprehend their ability to raise systemic 
as well as mucosal response. This work confirms that a simple ‘mix and inject’ formulation of 
nanoparticles and modular capsomeres can lead to effective adjuvanting of antigenic modular 
capsomeres by nanoparticles, with level of antibody response reliant on physicochemical properties 
of nanoparticles. The non-carrier adjuvanting effect of silica nanoparticles on modular capsomere 
was observed despite independent in vivo trafficking of nanoparticles and capsomeres, as visualized 
by fluorescence imaging. To the best of my knowledge, this work is the first to demonstrate the 
efficacy of sublingually-administered modular VLPs-based GAS vaccine and visualize their in vivo 
trafficking. These sublingually-administered modular VLPs induced high mucosal and systemic 
responses, which was aided by the observed draining of VLPs into submandibular lymph nodes and 
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in parallel with rapid absorption into systemic circulation. More importantly, the induced salivary 
antibodies opsonized GAS in vitro. This work also reports the potential of a freeze-dried 
formulation of modular VLPs as a cold-chain free, cost-effective GAS vaccine especially for poor 
remote regions which are most affected by GAS diseases. The outcomes of this thesis foster the 
development of modular VLPs and capsomeres targeting GAS and influenza A, respectively, and 
highlights the flexibility of MPyV VP1 based microbial vaccine platform to cater to the need for 
low-cost, rapid response and safe and efficacious vaccines.  
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Chapter 1 
 
Project Overview 
 
Vaccination has profound effect on the quality of human health. Vaccine development is moving 
towards the antigenic subunit approach, which is well-characterized and purified, with a good safety 
profile. As this new generation of subunit vaccines typically exhibit lower immunogenicity, 
formulations that augment antigen effectiveness are increasingly important [1, 2]. For designing 
effective and potent subunit vaccines, one main approach is to mimic the immunogenic properties 
of pathogen such as size, geometry, kinetics and molecular patterns [3]. Based on this approach, 
various vaccine delivery systems have been explored and virus-like particles (VLPs) is one such 
delivery platform that mimics viruses. VLPs and their subunits have been used as carrier systems 
for a variety of antigens derived from pathogens different from parent viruses [4-6]. Adjuvants are 
also employed to enhance the immunogenicity of subunit vaccines. 
 
1.1 Virus-like particles as a vaccine platform 
VLPs are macromolecular assemblies of biocompatible capsid proteins lacking infectious genetic 
material [4, 7]. VLPs were initially explored as parental vaccines [4, 5] and have demonstrated 
success as commercial products to date with the availability of VLP-based vaccines for cervical 
cancer, hepatitis B and hepatitis E approved for human use [5, 8, 9]. VLPs are self-adjuvanting and 
highly immunostimulatory owing to their particle characteristics and highly ordered repetitive 
structures [4, 7, 10, 11]. These properties make them an attractive delivery system for vaccines. 
Modular VLPs are being employed as delivery vehicles against diseases different from parent virus 
through incorporation of antigenic modules on the unrelated VLP structure [12-15]. 
 
A microbial vaccine platform for the production of VLP-forming viral capsid protein VP1 from 
murine polyomavirus (MPyV) has been developed [14, 16]. Five VP1 monomers self-assemble into 
a pentameric capsomere, and 72 copies of these capsomeres assemble into a VLP (Figure 1.1). 
Production of these VLPs occurs in three main stages: initially highly soluble recombinant VP1 
proteins are expressed in Escherichia coli (E.coli); followed by purification using standard 
optimized chromatography methods, and lastly, purified capsomeres are assembled in vitro into 
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VLPs under specific physicochemical conditions. This microbial platform has the potential to 
deliver safe and potent vaccines, quickly and cost effectively [14, 17]. 
 
 
Figure 1.1: Structure of murine polyomavirus VP1 protein. A) VP1 monomer. B) Capsomere 
(pentamer). C) Virus-like Particle. 
 
1.2 Capsomeres as an alternative vaccine platform 
Capsomeres are structural building subunits of a VLP formed by viral capsid proteins. Capsomeres 
can be produced by in vivo self-assembly of VP1 capsid proteins in cheap prokaryotic E.coli [18, 
19]. Manufacturing of capsomere is simpler, faster and cheaper as VLP assembly step is eliminated 
and thus can be considered as an alternative capsid protein-based vaccine. 
 
Recent studies using subunit modular capsomeres, which present antigens from Influenza A virus 
[14, 20], Group A Streptococcus (GAS) [21], human syncytial virus [22], and human mucin-1 
cancer [23], elucidate its advantages including improved tolerance to foreign epitopes insertion 
[24], enhanced stability [25-27] and easier and simplified production [14, 28]. Thus, these 
microbially-produced capsomeres have potential to be robust and flexible platform for vaccine 
production. VLPs and capsomeres possess pathogen-associated molecular patterns (PAMPs), which 
can efficiently crosslink innate pathogen-recognition receptors, delivering activating signals to the 
cells of the immune system [29]. However, even though capsomeres retain the molecular activating 
signals of the viruses, absence of particulate structure of VLP, necessitates the use of an adjuvant in 
their formulation [14, 20]. 
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1.3 Nanoparticles as adjuvant in vaccine formulation 
Adjuvants are generally employed in vaccine formulations to improve the potency of the antigens in 
terms of strength and quality of immune response with minimum risk of toxic side effects [30]. In 
addition, lower amount of antigen or reduced number of immunizations can be achieved with use of 
adjuvants [31]. Nanoparticles as adjuvant offer advantages in terms of structural stability, low cost 
and tailorable physicochemical properties such as size, shape, surface properties, and composition 
[30, 32]. Moreover, due to size similarity to the majority of pathogens, nanoparticles can be 
processed potently by the immune system and thus result in an effective immune response.  
 
Nanoparticles are exploited as adjuvant either i) as a delivery system for targeted delivery of 
antigen or to prolong the release of antigen or to protect antigen from degradation, and/or ii) as an 
immunopotentiator to enhance the cell-mediated or humoral immunity [32]. For vaccine delivery 
application, antigens are either encapsulated, chemically conjugated or adsorbed on the surface of 
the nanoparticles [33, 34], while for immunopotentiating activity of nanoparticles, such interaction 
is not necessary [35-37]. Emulsion-based adjuvants MF59TM and AS03TM have shown adjuvanting 
activity for antigens despite separate independent injection of both the components [35, 36]. This 
non-attachment adjuvanting effect has recently been observed for a simple mixture of silica 
nanoparticles and complex antigen capsomere, which has inherent viral molecular structure [37]. It 
is unknown whether similar adjuvanting efficacy will be observed for different types of 
nanoparticles of similar size, such as biodegradable Poly (D,L-lactic-co-glycolic acid) (PLGA) and 
Poly caprolactone (PCL) nanoparticles.  
 
1.4 Research objectives 
The overall aim of this PhD thesis is to develop effective nanovaccine formulations based on virus-
like particles and capsomeres targeting influenza A and GAS. 
 
This PhD thesis improved the efficacy of promising vaccine candidates previously developed within 
the research group by employing different formulation strategies. Nanoparticles were exploited to 
potentiate the immune response of the candidates. Based on the nature of targeted diseases, different 
routes of administration including parenteral and non-parenteral were evaluated to maximize the 
immune response needed for protective immunity. In addition, freeze-dried formulation of vaccine 
candidates was investigated to contribute to their translational potential, especially for poor 
developing countries which require long shelf-life of vaccine and cold-chain free storage and 
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transportation. These strategies were aided by tools such as in vivo imaging to understand and 
support their effectiveness in inducing desired immune response. This combinational approach was 
explored to augment the effectiveness of promising microbially-produced vaccine candidates 
targeting diseases that require low-cost, safe and rapid response vaccine. 
 
The following research objectives are addressed in this thesis: 
I. to evaluate the adjuvanting efficacy of different nanoparticles for modular capsomeres; 
II. to visualize the in vivo trafficking of silica nanoparticles-adjuvanted modular capsomeres 
formulation, and; 
III. to investigate the efficacy of sublingually-administered modular VLPs and their in vivo 
trafficking. 
 
The rationale behind each of these research objectives is explained in the following sections. 
 
1.4.1 Non-carrier nanoparticles as adjuvant for modular capsomeres 
Studies suggest that adjuvant enhances the immune response as either a delivery system and/or as 
an immunostimulant [32, 38]. Previous study has shown that modularization of weakly 
immunogenic M2e peptide from influenza A virus into viral modular capsomere results in high 
immunogenicity in mice [20]. In a follow up study, the effect of particle size on adjuvanting 
efficacy of non-carrier silica particles for these modular capsomeres has also been observed 
previously [37]. This leads to interesting research questions: 1) Would adjuvanting effect differ for 
different nanoparticles of similar size for a particular complex antigen? and 2) Does surface charge 
affect the adjuvanting efficacy of these nanoparticles? Thus, this study aims to evaluate the 
adjuvanticity of different nanoparticles ranging from biocompatible silica nanoparticles to 
biodegradable PLGA and PCL nanoparticles of similar sizes for modular capsomeres presenting 
influenza M2e antigen in vivo.  
 
1.4.2 In vivo trafficking of mixed nanoparticle and modular capsomere vaccine formulation 
Size-dependent non-carrier adjuvanting effect of silica nanoparticles for modular capsomere 
formulation has been observed previously [37]. To have a better understanding of the effect of 
biodistribution on the immune response induced by the formulations, in vivo trafficking of modular 
capsomere alone and its formulations with non-carrier silica nano-and micro-sized silica particles 
will be visualized by fluorescence optical imaging technique [39, 40]. This will answer the 
following research questions: 1) Whether these components (modular capsomeres and adjuvant 
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particles) traffic together or separately? and 2) Where they traffic in the body, even though it has 
already been shown that there is no interaction between the components before injection?  
 
1.4.3 Efficacy of sublingually-administered modular VLPs and their in vivo trafficking 
The main portal of entry for GAS are mucosal surfaces, thus sublingual delivery is a promising 
route of administration to provide protective immunity owing to its ability to induce systemic and 
mucosal immune response [41, 42]. Based on the previously reported successful outcomes with 
modular VLPs presenting GAS J8 antigen (J8-VLPs) [10, 14] and advantages associated with 
sublingual delivery [42], sublingual route of administration for J8-VLPs will be evaluated to 
determine whether they can induce high levels of serum IgG (systemic) and saliva IgA (mucosal) 
antibody needed for protective immunity against GAS infections. Fluorescence imaging study to 
visualize the in vivo trafficking of these sublingually-administered J8-VLPs will answer the 
following questions: 1) Where do they traffic into the body? and 2) Can their localized trafficking 
provide an insight into their ability to induce specific immune response? Mucosal adjuvants such as 
cholera toxin (CT) are generally used to enhance the immune response of antigens administered via 
mucosal routes [43, 44]. Freeze-dried formulation of J8-VLPs, which will bypass cold-chain storage 
and transportation, and reduce the cost will be ideal for catering to the needs of the poor and remote 
developing countries, which are most affected by GAS-related diseases. In vitro stability of freeze 
dried formulation of J8-VLPs has been demonstrated in a previous study [45], but the 
immunogenicity of these freeze-dried formulation has not been investigated. Thus, this in vivo 
immunogenicity study will further address the following questions: 3) Can mucosal adjuvant CT 
improve the immune response induced by sublingually-administered J8-VLPs? and 4) Does freeze-
drying process affect the immunogenicity of sublingually-administered J8-VLPs? Moreover, in 
vitro bactericidal assay will be carried out to evaluate whether the antibodies induced by different 
sublingually-administered J8-VLP formulations can promote bacterial clearance. 
 
1.5 Thesis organization 
This PhD thesis consists of 6 chapters including this introductory chapter. 
 
Chapter 2 provides a literature review of key topics relevant to this thesis. This includes a review on 
the vaccine platform based on the murine polyomavirus, use of nanoparticles in vaccinology, 
sublingual delivery, in vivo molecular imaging, and influenza and GAS as the target diseases 
investigated in this thesis.  
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Chapter 3 investigates the adjuvanting efficacy of different nanoparticles as non-carrier adjuvants 
for modular capsomeres presenting influenza M2e antigen through in vivo immunogenicity tests. 
 
Chapter 4 examines the in vivo trafficking of silica nanoparticles-adjuvanted modular capsomeres 
presenting influenza M2e antigen. 
 
Chapter 5 evaluates the efficacy of sublingually-administered modular VLPs presenting GAS J8 
antigen through in vivo immunogenicity tests. It also evaluates the effect of mucosal adjuvant and 
freeze-drying on the induced antibody levels and in vivo trafficking of sublingually-administered 
modular VLPs presenting GAS J8 antigen. 
 
Chapter 6 discusses the summary of key findings and outlines future directions for further research. 
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Chapter 2 
 
Literature review 
 
Section 2.2 in this chapter consists of the peer-reviewed paper published as: 
 
Zhao L†, Seth A†, Wibowo N, Zhao C-X, Mitter N, Yu C, Middelberg APJ (2014). Nanoparticle 
vaccines. Vaccine 32(3): 327-337. 
†These authors contributed equally. 
 
The following modifications were made to the article:  
− Page numbers of the original article were changed into the numbers consistent with those on 
the remainder of the thesis page numbers.  
− Figure numbers were changed into the numbers consistent with the remainder of figures in 
the thesis.  
− Section and sub-section numbers were changed into the numbers consistent with the 
remainder of sections and sub-sections in all chapters of the thesis.  
− The reference style of the original article was changed into the style consistently used in all 
chapters of the thesis. 
 
2.1 Introduction 
This chapter provides a review of key topics relevant to the research objectives in this thesis. 
 
The use of nanoparticles in vaccinology is reviewed in Section 2.2 by initially discussing the type of 
nanoparticles utilized for prophylactic vaccine design. The interaction of nanoparticles with antigen 
of interest is further discussed, classifying the role of nanoparticles as either a delivery system or an 
immunopotentiator adjuvant, followed by reporting their interaction with antigen presenting cells 
and the biological system.  
 
Virus-like particles (VLPs) and their subunit capsomeres are reviewed by discussing their 
applications in the field of vaccinology, along with their characteristic features. The role of VLPs 
and capsomeres as antigenic carriers and their efficacies in preclinical and clinical studies are 
reported. In Section 2.4, virus geometry of murine polyomavirus (MPyV), production of VLP and 
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capsomere from MPyV VP1 and application of MPyV VP1 VLP and capsomere as antigen carriers 
are discussed. 
 
Two target diseases, namely influenza A and Group A streptococcus (GAS) in this project are 
reviewed in detail in Section 2.5 and 2.6. In addition to the information related to pathogens, the 
burden of diseases and current issues associated with them are reported. Vaccine strategies against 
these diseases are discussed with special emphasis on peptide-based vaccines. Relevant information 
on antigenic M2e and J8 peptides for influenza and GAS respectively is provided, as these are the 
antigens used in this work for presentation on the MPyV VLP or capsomere vaccine platform. 
 
One of the objectives of this current thesis is to explore the sublingual delivery of modular VLPs. 
Section 2.7 provides a brief review of different non-parenteral routes of administration including 
their advantages and disadvantages, with special emphasis on sublingual route. Current status and 
challenges associated with sublingual vaccine delivery are also reported.  
 
In vivo molecular imaging techniques are reviewed in Section 2.8 by providing an overview of 
different techniques, highlighting their various features. Fluorescence imaging technique is 
discussed in detail, as it is the imaging technique used in this work to visualize the in vivo 
trafficking of the components of vaccine formulations of interest. 
 
2.2 Nanoparticles in vaccinology 
Vaccine development has a proud history as one of the most successful public health interventions 
to date. Vaccine development is historically based on Louis Pasteur’s “isolate, inactivate, inject” 
paradigm. As vaccine development moves increasingly to draw on modern concepts of rational 
design, the number of candidate vaccines is increasing [1, 2]. Most candidate vaccines represent 
“minimalist” compositions [3], which typically exhibit lower immunogenicity. Adjuvants and novel 
delivery systems that boost immunogenicity are increasingly needed as we move toward the era of 
modern vaccines. 
 
Nanotechnology offers the opportunity to design nanoparticles varying in composition, size, shape, 
and surface properties, for application in the field of medicine [4, 5]. Nanoparticles, because of their 
size similarity to cellular components, can enter living cells using the cellular endocytosis 
mechanism, in particular pinocytosis [6]. These cutting-edge innovations underpinned a market 
worth US$6.8 billion in 2006 [7], which increased to US$78.4 billion in 2012 and is predicted to 
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reach US$177.60 billion by 2019 [8]. Indeed, nanoparticles are revolutionizing the diagnosis of 
diseases as well as the delivery of biologically-active compounds for disease prevention and 
treatment. The emergence of virus-like particles (VLPs) and the resurgence of nanoparticles, such 
as quantum dots and magnetic nanoparticles, marks a convergence of protein biotechnology with 
inorganic nanotechnology that promises an era of significant progress for nanomedicine [9, 10]. A 
number of approved nano-sized vaccine and drug delivery systems highlight the revolution in 
disease prevention and treatment that is occurring [4, 11-13]. 
 
 
Figure 2.1: Number of publications returned using the search terms “nanoparticle* and 
vaccin*” from Web of Science (http://apps.webofknowledge.com/; results for a search conducted 
on 20 October 2016). 
 
The use of nanotechnology in vaccinology, in particular, has been increasing exponentially in the 
past decade (Figure 2.1), leading to the birth of “nanovaccinology” [3]. In both prophylactic and 
therapeutic approaches, nanoparticles are used as either a delivery system to enhance antigen 
processing and/or as an immunostimulant adjuvant to activate or enhance immunity. Therapeutic 
nanovaccinology is mostly applied for cancer treatment [14-16], and is increasingly explored to 
treat other diseases or conditions, such as Alzheimer’s [17], hypertension [9], and nicotine addiction 
[11]. Prophylactic nanovaccinology, on the other hand, has been applied for the prevention of 
different diseases. A number of prophylactic nanovaccines have been approved for human use and 
more are in clinical or pre-clinical trials [13, 18-20]. 
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Figure 2.2: The size range of nanoparticles used in nanovaccinology. 
 
2.2.1 Types of nanoparticles 
2.2.1.1 Polymeric nanoparticles 
A great variety of synthetic polymers are used to prepare nanoparticles, such as poly (D,L-lactide-
co-glycolide)(PLG) [21-23], poly (D,L-lactic-coglycolic acid)(PLGA) [21, 24-29], poly (g-glutamic 
acid) (g-PGA) [30, 31], poly (ethylene glycol) (PEG) [23], and polystyrene [32, 33]. PLG and 
PLGA nanoparticles have been the most extensively investigated due to their excellent 
biocompatibility and biodegradability [34, 35]. These polymeric nanoparticles entrap antigen for 
delivery to certain cells or sustain antigen release by virtue of their slow biodegradation rate [26-28, 
30, 35]. PLGA has been used to carry antigen derived from various pathogens including 
Plasmodium vivax with mono-phosphoryl lipid A as adjuvant [36], hepatitis B virus (HBV) [21], 
Bacillus anthracis [28], and model antigens such as ovalbumin and tetanus toxoid [25, 26].  Poly(g-
glutamic acid) (g-PGA) nanoparticles are comprised of amphiphilic poly(amino acid)s, which self-
assemble into nano-micelles with a hydrophilic outer shell and a hydrophobic inner core [30, 31]. g-
PGA nanoparticles are generally used to encapsulate hydrophobic antigen [30, 31]. Polystyrene 
nanoparticles can conjugate to a variety of antigens as they can be surface-modified with various 
functional groups [32, 37].  
 
Natural polymers based on polysaccharide have also been used to prepare nanoparticle adjuvants, 
such as pullulan [38, 39], alginate [40], inulin [41, 42], and chitosan [43-48]. In particular, chitosan-
based nanoparticles have been widely studied due to their biocompatibility, biodegradability, 
nontoxic nature and their ability to be easily modified into desired shapes and sizes [30, 49, 50]. 
These nanoparticles have been used in the preparation of various vaccines including HBV vaccines 
[48], Newcastle disease vaccines [47], and DNA vaccines [43, 45, 46]. Inulin, a well-known 
activator of complement via the alternative pathway [51], is also a potent adjuvant. Nanoparticle 
adjuvants derived from inulin, such as Advax™, have shown enhancement of immune response in 
vaccines against various viruses including influenza [41] and hepatitis B [42]. 
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Polymers, such as PLA, PLGA, PEG, and natural polymers such as polysaccharides [40, 52-54], 
have also been used to synthesize hydrogel nanoparticles, which are a type of nano-sized 
hydrophilic three-dimensional polymer network. Nanogels have favorable properties including 
flexible mesh size, large surface area for multivalent conjugation, high water content, and high 
loading capacity for antigens [54, 55]. Chitosan nanogels have been widely used in antigen 
delivery, such as Clostridium botulinum type-A neurotoxin subunit antigen Hc for an adjuvant-free 
intranasal vaccine [56], and recombinant NcPDI antigen for Neospora caninum vaccination [57]. 
 
2.2.1.2 Inorganic nanoparticles 
Many inorganic nanoparticles have been studied for their use in vaccines. Although these 
nanoparticles are mostly non-biodegradable, the advantage of them lies in their rigid structure and 
controllable synthesis [32]. Gold nanoparticles (AuNPs) are used in vaccine delivery [34], as they 
can be easily fabricated into different shapes (spherical, rod, cubic, etc.) [58] with a size range of 2-
150 nm [59]. Gold nanorods have been used as a carrier for an antigen derived from respiratory 
syncytial virus by conjugating the antigen to the surface [60]. Other types of gold nanoparticles 
have been used as carriers for antigens derived from other viruses such as influenza [61] and foot-
and-mouth disease [62], or as a DNA vaccine adjuvant for human immunodeficiency virus (HIV) 
[63].  
 
Carbon nanoparticles are another commonly-studied composition for drug and vaccine delivery 
[59]. They are known for their good biocompatibility and can be synthesized into a variety of 
nanotubes and mesoporous spheres [64-66]. The diameter of carbon nanotubes (CNTs) used as 
carriers is generally 0.8-2 nm with a length of 100-1000 nm [67, 68], while the size of mesoporous 
carbon spheres is around 500 nm [65]. Multiple copies of protein and peptide antigens can be 
conjugated on to CNTs for delivery and have enhanced the level of IgG response [65, 67-69]. 
Mesoporous carbon nanoparticles have been studied for application as an oral vaccine adjuvant 
[65]. 
 
One of the most promising inorganic materials for nanovaccinology and delivery system design is 
silica. Silica-based nanoparticles (SiNPs) are biocompatible and have excellent properties as 
nanocarriers for various applications, such as selective tumor targeting [70], real-time multimodal 
imaging [71], and vaccine delivery. The SiNPs can be prepared with tunable structural parameters. 
By controlling the sol–gel chemistry, the particle size and shape of SiNPs can be adjusted to 
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selectively alter their interaction with cells [72]. The abundant surface silanol groups are beneficial 
for further modification to introduce additional functionality, such as cell recognition, absorption of 
specific biomolecules, improvement of interaction with cells, and enhancement of cellular uptake 
[73-76]. In addition, porous SiNPs such as mesoporous silica nanoparticles (MSNs) and hollow 
SiNPs can be prepared by templating methods, which can be applied as a multifunctional platform 
to simultaneously deliver cargo molecules with various molecular weights [72]. MSNs with sizes in 
the range of 50-200 nm have been studied as both nano-carriers and adjuvants for delivery of 
effective antigens [77-79], such as those derived from porcine circovirus [80] and HIV [81]. MSNs 
can be used to control the release of antigens by controlling the shape, pore size and surface 
functionalization [77, 82]. Compared to solid SiNPs, MSNs have higher loading capacity for their 
larger specific surface area, and better performance in delivery and controlled release due to the 
tunable hollow and mesoporous structure. In addition, MSNs can be degraded which can then be 
excreted in the urine [83-85]. With these properties, MSNs show potential to become high-
efficiency, controlled-release nano-carriers in future vaccine formulations. 
 
Calcium phosphate nanoparticles can be created by mixing calcium chloride, dibasic sodium 
phosphate and sodium citrate under specific conditions [86, 87]. They are non-toxic and can be 
formed into a size of 50-100 nm [88]. These nanoparticles are useful adjuvants for DNA vaccines 
and mucosal immunity [77, 86-88], and show excellent biocompatibility. 
 
2.2.1.3 Liposomes 
Liposomes are formed by biodegradable and nontoxic phospholipids. Liposomes can encapsulate 
antigen within the core for delivery [89] and incorporate viral envelope glycoproteins to form 
virosomes [90, 91] including for influenza [92]. Combination of 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP) modified cationic liposome and a cationic polymer (usually 
protamine) condensed DNA are called liposome-polycation-DNA nanoparticles (LPD), a 
commonly used adjuvant delivery system in DNA vaccine studies [93, 94]. The components of 
LPD spontaneously rearrange into a nano-structure around 150 nm in size with condensed DNA 
located inside the liposome [94]. Liposomes modified with maleimide can be synthesized into 
interbilayer-crosslinked multilamellar vesicles (ICMVs) by cation driven fusion and crosslinking 
[95] enabling slowed release of entrapped antigen. A number of liposome systems have been 
established and approved for human use, such as Inflexal® V and Epaxal®, which have been 
discussed in other reviews [89, 96]. 
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2.2.1.4 Immunostimulating complex (ISCOM) 
ISCOMs are cage like particles about 40 nm large in size, made of the saponin adjuvant Quil A, 
cholesterol, phospholipids, and protein antigen [34, 90, 97-99]. These spherical particles can trap 
the antigen by apolar interactions [34]. ISCOMATRIX comprises ISCOMs without antigen [34, 90, 
98, 100]. ISCOMATRIX can be mixed with antigen, enabling a more flexible application than is 
possible for ISCOMs, by removing the limitation of hydrophobic antigens [34]. Various antigens 
have been used to form ISCOMs, including antigens derived from influenza [101, 102], herpes 
simplex virus [103], HIV [104], and Newcastle disease [97]. 
 
2.2.1.5 Virus-like particles 
Virus-like particles (VLP) are self-assembling nanoparticles, lacking infectious nucleic acid, formed 
by self-assembly of biocompatible capsid proteins [105, 106]. VLPs are the ideal nanovaccine 
system as they harness the power of evolved viral structure, which is naturally optimized for 
interaction with the immune system, but avoid the infectious components. VLPs take the good 
aspects of viruses and avoid the bad. The naturally-optimized nanoparticle size and repetitive 
structural order means that VLPs induce potent immune responses, even in the absence of adjuvant 
[107]. VLP based vaccines are the first nanoparticle class to reach market – the first VLP vaccine 
for Hepatitis B virus was commercialized in 1986 [108] and have become widely administered in 
healthy populations. In nanovaccinology, VLP nanoparticles have the strongest evidence base for 
safe use in healthy humans. Newer VLP vaccines for human papillomavirus [109] and Hepatitis E 
[110] have been approved for use in humans in 2006 and 2011, respectively. 
 
VLPs can be derived from a variety of viruses (Figure 2.3) [105], with sizes ranging from 20 to 800 
nm [13, 111], and can be manufactured with a variety of process technologies [112]. The historical 
approach to VLP manufacture involves an in vivo route, where the assembly of capsid proteins into 
VLPs occurs inside the expression host. The assembled particle is then purified away from adherent 
and encapsulated contaminants.  In some cases it becomes necessary to disassemble and then re-
assemble the VLP to improve quality [112]; recently-approved VLP vaccines typically include 
some aspect of extracellular assembly within the processing regime. An emerging approach for 
VLP assembly is through cell-free in vitro processing [113-117]. This approach inverts the 
traditional assemble-then-purify paradigm; large-scale purification of the VLP building blocks from 
contaminants occurs first, then these are assembled in vitro, avoiding the need to disassemble VLP 
structures after assembly in a cell. Further review of VLP manufacturing approaches is available 
elsewhere [13, 19, 118, 119]. 
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Figure 2.3: Structure of virus-like particles. Virus-like particles can be derived from a variety of 
viruses. Adapted from [105]. 
 
VLPs commercialized to date are based on self-assembly of proteins derived from the target virus. 
However, VLPs can also act as a delivery platform where a target antigen from a virus unrelated to 
the VLP used is modularized on the surface of a VLP [20, 120-123]. These modular VLPs exploit 
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known benefits of VLPs (optimized particle size and molecular structure) to target disease in an 
engineered fashion. With many VLP vaccines currently in clinical or pre-clinical trials [13, 19], an 
increase in the number of approved VLP-based vaccines can be expected. 
 
2.2.1.6 Self-assembled proteins 
Recognizing the power of the VLP approach, self-assembling systems that attempt to drive higher 
levels of protein quaternary structuring have emerged for the preparation of nanoparticle-based 
vaccines. Ferritin is a protein that can self-assemble into nearly-spherical 10 nm structure [124]. By 
genetically fusing influenza virus hemagglutinin (HA) to ferritin, the recombined protein 
spontaneously assembled into an octahedrally-symmetric particle and reformed 8 trimeric HA 
spikes [124] to give a higher immune response than trivalent inactivated influenza vaccine, which 
typically is processed to destroy rather than build viral structure. This example highlights the 
importance of driving higher-order molecular structure in modern vaccines. The major vault protein 
(MVP) is another kind of self-assembling protein. Ninety-six units of MVP can self-assemble into a 
barrel-shaped vault nanoparticle, with a size of approximately 40 nm wide and 70 nm long [125]. 
Antigens that are genetically fused with a minimal interaction domain can be packaged inside vault 
nanoparticles by self-assembling process when mixed with MVPs [125]. Vault nanoparticles have 
been used to encapsulate the major outer membrane protein of Chlamydia muridarum for studies of 
mucosal immunity [125]. 
 
2.2.1.7 Emulsions 
Another type of nanoparticles used as adjuvants in vaccine delivery is nano-sized emulsions [98, 
126, 127]. These nanoparticles can exist as oil-in-water or water-in-oil forms, where the droplet size 
can vary from 50-600 nm [126]. Emulsions can carry antigens inside their core for efficient vaccine 
delivery [126] or can also be simply mixed with the antigen. One commonly-used emulsion is 
MF59, an oil-in-water emulsion which has been licensed as a safe and potent vaccine adjuvant in 
over 20 countries [34, 128]. It has been widely studied for use in influenza vaccines [128-130]. 
Another is MontanideTM, a large family of both oil-in-water and water-in-oil emulsions, including 
ISA 50V, 51, 201, 206 and 720 [34, 131]. Montanide ISA 51 and 720 have been used in Malaria 
vaccines [132, 133], Montanide ISA 201 and 206 have been used in foot-and-mouth disease 
vaccines [134]. 
 
Recently, a tailorable nano-sized emulsion (TNE) platform technology has been developed using 
non-covalent click self-assembly for antigen and drug delivery [135, 136]. An oil-in-water 
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nanoemulsion is formed using designed biosurfactant peptides and proteins. Using a self-
assembling peptide-protein system, immune-evading poly-ethylene glycol (PEG) and a receptor-
specific antibody can be arrayed in a selectively proportioned fashion on the aqueous interface of a 
nano-sized oil-in-water emulsion (Figure 2.4). Targeted delivery of protein antigen to dendritic cells 
was achieved [136]. This work demonstrates a new and simple way to make biocompatible designer 
nanoemulsions using non-covalent click self-assembly by sequential top-down reagent addition. 
 
 
 
Figure 2.4: Schematic representation of PEG (white) chemically conjugated to DAMP4 protein 
(dark blue) being introduced to a solution containing pre-formed nanoemulsion oil core (light 
yellow) stabilized by AM1 peptide (red), in aqueous buffer (light blue background). DAMP4 
protein, which is chemically similar to AM1 peptide, is able to integrate into the oil-water interface 
formed between the core and the aqueous bulk. Prior conjugation of PEG to DAMP4 leads to its 
functional display at the interface through non-covalent molecular self-assembly. Adapted from 
[136]. 
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2.2.2 Nanoparticle interaction with antigen 
Vaccine formulations comprising nanoparticles and antigens can be classified by nanoparticle 
action into those based on delivery system or immune potentiator approaches. As a delivery system, 
nanoparticles can deliver antigen to the cells of the immune system, i.e. the antigen and nanoparticle 
are co-ingested by the immune cell, or act as a transient delivery system, i.e. protect the antigen and 
then release it at the target location [77]. For nanoparticles to function as a delivery system, 
association of antigen and nanoparticle is typically necessary. For immune potentiator approaches, 
nanoparticles activate certain immune pathways which might then enhance antigen processing and 
improve immunogenicity. 
 
Hard material nanoparticles, such as those based on silica, gold, and calcium phosphate, have 
predominantly been examined for use as a delivery system [137] and have thus been engineered to 
promote antigen attachment. Attachment of antigen has been achieved through simple physical 
adsorption or more complex methods, such as chemical conjugation or encapsulation (Figure 2.5). 
Adsorption of antigen onto a nanoparticle is generally based simply on charge or hydrophobic 
interaction [77, 138, 139]. Therefore, the interaction between nanoparticle and antigen is relatively 
weak, which may lead to rapid disassociation of antigen and nanoparticle in vivo. Encapsulation and 
chemical conjugation provide for stronger interaction between nanoparticle and antigen. In 
encapsulation, antigens are mixed with nanoparticle precursors during synthesis, resulting in 
encapsulation of antigen when the precursors particulate into a nanoparticle [86]. Antigen is 
released only when the nanoparticle has been decomposed in vivo or inside the cell. On the other 
hand, for chemical conjugation, antigen is chemically cross-linked to the surface of a nanoparticle 
[140]. Antigen is taken up by the cell together with the nanoparticle and is then released inside the 
cell. In soft matter nanoparticle delivery system, such as those based on VLPs, ISCOM, 
ISCOMATRIXTM, or liposomes, attachment of antigen is achieved through chemical conjugation, 
adsorption, encapsulation, or fusion at DNA level [89, 92, 99, 100, 121-123].  
 
For nanoparticles to act as an immune potentiator, attachment or interaction between the 
nanoparticle and antigen is not necessary, and may be undesirable in cases where modification of 
antigenic structure occurs at the nanoparticle interface. Soft-matter nanoparticles, such as emulsion-
based adjuvants MF59TM and AS03TM, have been shown to adjuvant a target antigen even when 
they are injected independently of, and before, the antigen [141, 142]. Building on this idea, 
formulation of immune potentiator nanoparticles with a target antigen could be possible through 
simple mixing of nanoparticle and adjuvant, shortly prior to injection, with minimal association 
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between nanoparticle and antigen needed. This approach has only recently been investigated for 
hard-material nanoparticle adjuvants, with results suggesting that nanoparticles may act as a size-
dependent immune potentiator adjuvant even when not conjugated to the antigen [143]. This new 
finding is consistent with a number of other studies that have demonstrated induction of 
inflammatory immune responses after injection of hard material nanoparticles alone and without 
antigen [144, 145]. Further studies into the use of nanoparticles as immune-potentiating adjuvants 
are clearly needed. As the interaction of nanoparticles with the immune system becomes more fully 
understood, we expect their impact to be broadened. 
 
 
Figure 2.5: Interaction of nanoparticle with antigen of interest. Formulation of nanoparticle and 
antigen of interest can be through attachment (e.g. conjugation, encapsulation, or adsorption) or 
simple mixing. 
 
2.2.3 Nanoparticle interactions with antigen presenting cells 
Incorporating antigenic components into nanoparticles has attracted extensive interest with a focus 
on how to deliver antigen more efficiently to antigen presenting cells (APCs) and subsequently 
induce their maturation and cross presentation of antigen for activation of a potent immune response 
[146-150]. As specialized APCs which efficiently uptake and process antigen, dendritic cells (DCs) 
and macrophages are often targeted in vaccine design. Good understanding of DC and macrophage 
uptake mechanisms and interactions of NPs with these cells is therefore very important for 
developing efficacious nanoparticle vaccines [151-153]. Studies have reported that size, charge and 
shape of nanoparticles play significant roles in antigen uptake. 
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Generally, nanoparticles having a comparable size to pathogens can be easily recognized and are 
consequently taken up efficiently by APCs for induction of immune response [154-160]. DCs 
preferentially uptake virus-sized particles (20 – 200 nm) while macrophages preferentially uptake 
larger particles (0.5 – 5 µm) [154]. In an in vitro study using polystyrene particles ranging from 
0.04-15 µm, the optimum size for DC uptake was found to be smaller than 500 nm [161]. Similarly, 
300 nm sized poly (lactide-co-glycolide) (PLGA) particles also showed higher internalization and 
activation of DCs in comparison to 17, 7 and 1 µm particles [162]. Higher uptake of smaller 
polylactide (PLA) particles (200-600 nm) in comparison to larger ones (2-8 µm) has also been 
reported for uptake by macrophages [163]. Different studies however, show discrepancies in 
optimum nanoparticle vaccine size. Amphiphilic poly(amino acid) (PAA) nanoparticles of 30 nm 
were shown to have a lower DC uptake than that of 200 nm nanoparticles [164]. Polyacrylamide 
hydrogel particles of 35 nm and 3.5 µm in size showed no difference in macrophages uptake [165]. 
These discrepancies may be related to the intrinsic differences in the material properties, with each 
material having an optimum size for induction of potent immune response [166].  
 
In addition to particle size, surface charge also plays a significant role in the activation of immune 
response. Cationic nanoparticles have been shown to induce higher APC uptake due to electrostatic 
interactions with anionic cell membranes [161]. In vitro studies suggested that a cationic surface 
can significantly enhance the uptake of polystyrene particles of micron size (~1 µm) by 
macrophages and DCs in comparison with a neutral or negative surface [161, 167, 168], but not for 
the smaller nanoparticles (100 nm) [161]. However, other in vivo studies revealed that either 
positively [169] or negatively charged [170] liposomes can act as efficient adjuvants to induce cell-
mediated immune response. Furthermore, due to their electrostatic interaction with anionic cell 
membranes, cationic particles are more likely to induce hemolysis and platelet aggregation than 
neutral or anionic particles [171].  
 
Particle shape plays an equally important role in the interaction between nanoparticles and APCs. 
For big particles (>1 µm), particle shape plays a dominant role in phagocytosis by macrophages as 
the uptake of particles is strongly dependent on the local shape at the interface between particles 
and APCs [172]. Worm-like particles with high aspect ratios (>20) exhibited negligible 
phagocytosis compared to spherical particles [173]. On the other hand, spherical gold nanoparticles 
(AuNPs) (40 nm) were more effective in inducing antibody response than other shapes (cube and 
rod) or the 20 nm-sized AuNPs, even though the rods (40×10 nm) were more efficient in APC 
uptake than the spherical and cubic AuNPs [58]. 
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A number of studies also reported the effect of hydrophobicity, showing higher immune response 
for hydrophobic particles than hydrophilic ones [174, 175]. A number of other factors such as 
surface modification (pegylation, targeting ligands) and vaccine cargo [44] have been shown to 
affect the interaction between nanoparticles and APCs as well.  
 
2.2.4 Nanoparticle-biosystem interactions  
Designing safe and efficacious nanoparticle vaccines requires a thorough understanding of the 
interaction of nanoparticles with biological systems, which then determines the fate of nanoparticles 
in vivo. Physicochemical properties of nanoparticles including size, shape, surface charge, and 
hydrophobicity influence the interaction of nanoparticles with plasma proteins [176, 177] and 
immune cells [174]. These interactions as well as morphology of vascular endothelium play an 
important role in distribution of nanoparticles in various organs and tissues of the body.  
 
The lymph node (LN) is a target organ for vaccine delivery since cells of the immune system, in 
particular B and T cells, reside there. Ensuring delivery of antigen to LNs for optimum induction of 
immune response is therefore an important aspect of nanoparticle vaccine design. Distribution of 
nanoparticles to the lymph node is mainly affected by size [178, 179]. Nanoparticles with a size 
range of 10-100 nm can penetrate the extracellular matrix easily and travel to the lymphatic nodes 
where they are taken up by resident DCs for activation of immune response [179-182]. Particles of 
larger size (>100 nm) linger at the administration point [181, 183, 184] and are subsequently 
scavenged by local APCs [182, 184, 185], while smaller particles (<10 nm) drain to the blood 
capillaries [179, 185]. The route of administration and biological environment to which 
nanoparticles are exposed could also affect the draining of nanoparticles to the LN. It was reported 
that small PEG (Polyethylene glycol) coated liposomes (80-90 nm) were significantly present in 
larger amounts in lymph nodes after subcutaneous administration as compared to intravenous and 
intraperitoneal administration [186]. 
 
In addition to targeting lymphatic organs for efficient activation of immune response, design of 
nanoparticle vaccines also needs to consider nanoparticle clearance from the body. Adverse effects 
may occur when nanoparticles are not degraded or excreted from the body and hence, accumulate in 
different organs and tissues. Clearance of nanoparticles could be achieved through degradation by 
the immune system or by renal or biliary clearance. 
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Renal clearance through kidneys can excrete nanoparticles smaller than 8 nm [187, 188]. Surface 
charge also plays an important role in determining renal clearance of nanoparticles. Few reports 
have suggested that for appropriate identically sized particles, based on surface charge, ease of renal 
clearance follows the order of positively-charged< neutral<negatively charged [189, 190]. This may 
be attributed to the presence of negatively-charged membrane of glomerular capillary [191]. 
 
On the other hand, biliary clearance through liver allows excretion of nanoparticles larger than 200 
nm [187, 192]. Surface charge also plays role in biliary clearance with increase in surface charges 
showing increased distribution of nanoparticles in the liver [193]. Furthermore, a study reported 
shape dependent distribution of nanoparticles where short rod nanoparticles were predominantly 
found in liver, while long rods were found in spleen. Short rod nanoparticles were excreted at a 
faster rate than longer ones [194]. 
 
In order to aid understanding of interaction of nanoparticles with immune cells and the biosystem, 
many different in vivo molecular imaging techniques including magnetic resonance imaging (MRI), 
positron emission tomography (PET), fluorescence imaging, single photon emission computed 
tomography (SPECT), X-ray computed tomography (CT) and ultrasound imaging can be employed. 
Owing to its excellent soft tissue contrast and non-invasive nature, MRI imaging is extensively used 
for obtaining three-dimensional images in vivo. Super paramagnetic iron oxide nanoparticles 
(SPION) have been extensively used as contrast agents for morphological imaging [114, 115]. PET 
usually employs an imaging device (PET scanner) and a radiotracer that is usually intravenously 
injected into the bloodstream. Due to high sensitivity of this technique, it is used to study the 
biodistribution of particles of interest. The only disadvantage of this technique is relatively low 
spatial resolution as compared to other techniques. PET imaging of 64Cu radiolabeled shell-
crosslinked nanoparticles has been demonstrated [116]. Fluorescence imaging facilitates imaging of 
nanoparticles using fluorescent tags. Dye-doped silica nanoparticles as contrast imaging agents for 
in vivo fluorescence imaging in small animals have been reported [195]. 
 
Nowadays, more attention is being paid to synergize two or more imaging techniques that 
complement each other and provide an opportunity to overcome shortcomings of individual 
techniques in terms of resolution or sensitivity. For instance, simultaneous PET-MRI imaging is a 
new emerging hybrid imaging system that combines the morphological imaging component of MRI 
with the functional imaging component of PET [113]. Multifunctionality of nanoparticles can be 
utilized for such hyphenated imaging. 
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2.3 Viral capsid protein-based vaccines 
VLP and their subunits, which are assemblies of viral capsid proteins, mimic the 
immunostimulating properties of viruses. They basically harness the different characteristic 
properties of viruses: highly ordered repetitive structure, ability to elicit innate immunity, kinetics 
and molecular patterns [149, 196]. 
 
2.3.1 Virus-like particles (VLPs) 
As discussed in detail in section 2.2.1.5. 
 
2.3.2 Capsomeres 
Capsomeres, which are structural building blocks of VLPs, are considered as an alternative capsid 
protein-based vaccine to VLPs. In case of capsomeres, the manufacturing process is simplified as 
capsomeres can be produced using cheap prokaryotic system such as Escherichia coli (E. coli) and 
complex process of in vitro assembly of VLPs is eliminated, which reduces the cost (Figure 2.6) 
[114-116]. Capsomeres have been further shown to be more stable [197-199] as well as more 
tolerant to foreign epitope insertion [200] than the related VLPs, these features indicate the 
robustness of capsomere-based vaccine.  
 
 
Figure 2.6: Microbial platform for VLP- and capsomere-based vaccines. Adapted from [201]. 
 
There have been limited studies exploring the potential of capsomere-based vaccine formulation so 
far. Some studies have reported excellent immunogenicity of capsomeres, even without adjuvant 
[197, 202-204], while other studies have reported their lower immunogenicity as compared to 
assembled VLPs, which could be enhanced to comparable level by formulating with adjuvant [205, 
206]. In addition to being explored as parental vaccine, capsomeres have also been modularized to 
present antigen from diseases different from parent viruses on its surface. Human papillomavirus 
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(HPV) L1 capsomeres have been used as carrier for display of foreign epitopes from influenza A 
virus [207], human syncytial virus [208] and human mucin-1 cancer antigen [202]. Similarly, 
murine polyomavirus VP1 capsomeres have been modularized to display antigens from group A 
streptococcus [209, 210] and influenza A virus [203] and were shown to elicit strong antigen-
specific immune responses on being formulated with adjuvant. 
 
2.4 Murine polyomavirus vaccine platform 
Murine polyomavirus (MPyV) is a non-enveloped, double stranded deoxyribonucleic acid (DNA) 
virus that belongs to the family Polyomaviridae. The capsid of MPyV comprise of 72 pentameric 
major capsid VP1 protein and minor core proteins VP2 and VP3 [211]. This capsid is icosahedral 
(T=7), which is 45 nm in diameter. Major capsid protein VP1 can self-assemble into virus-like 
particles (VLPs), even in the absence of other viral proteins, in proper physicochemical conditions 
[212].    
 
Self-assembly process of VLPs from MPyV VP1 capsid proteins involves the formation of 
intermediate pentameric subunit structure. Five VP1 protein monomer organise into pentameric 
capsomere and 72 capsomeres further assemble into a VLP [213]. E. coli is one of the most 
commonly used expression system for the production of recombinant protein since it is cheap, fast 
and easily scalable. This system has been used for production of polyomavirus [112, 214] and 
papillomavirus [215] capsid protein. In E. coli expression system, self -assembly of MPyV VP1 into 
capsomeres occurs and purified capsomeres can be further assembled in vitro into VLPs under 
specific physicochemical conditions. This microbial-based production platform has been optimised 
in terms of yield and purity [216] and even allows scaled up production of highly purified capsid 
protein at gram-per-litre levels [217]. MPyV capsid protein VP1 has been used to present antigenic 
modules from GAS [209, 210, 218], influenza [203, 210, 219] and rotavirus [220]. 
 
2.5 Influenza A 
2.5.1 Pathogen  
Influenza viruses are enveloped, single-stranded and segmented ribonucleic acid (RNA) viruses that 
belong to the family Orthomyxoviridae. Influenza viruses are classified into three serologically 
different types, designated as A, B and C, based on different factors such as antigenic differences in 
their nucleoprotein (NP) and matrix (M) proteins, range of hosts and number of gene segments and 
viral proteins [221]. Influenza B and C viruses can cause infection mostly in humans. Influenza A 
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that can infect different species including humans, birds, and pigs are further subtyped based on the 
properties of haemagglutinin (HA) and neuraminidase (NA) proteins subtypes and has the 
capability to cause pandemics. 
 
 
Figure 2.7: 3D model of influenza A virus. Adapted from Science Vol. 312, page 380 (21 April 
2006). 
 
Influenza A viruses contain eight RNA segments that encode ten proteins (Figure 2.7) [222]. These 
encoded viral proteins are PB1, PB2, and PA polymerases, haemagglutinin (HA), nucleoprotein 
(NP), neuraminidase (NA), matrix protein 1 (M1) and matrix protein 2 (M2), and non-structural 
protein 1 (NS1) and non-structural protein 2 (NS2). Their functions have been listed in Table 2.1. 
Currently, 16 HA and 9 NA subtypes are known to exist [223]. 
 
Mutations, including substitutions, deletions, and insertions, are one of the main reasons for 
variations in influenza viruses and contribute to their continuous evolution. The inability of its RNA 
polymerases to proofread results in errors during replication cycle. These subtle changes in its 
surface proteins are referred to as antigenic drift and result in new antigenic variants of influenza A 
viruses [221, 222]. The influenza A viruses can also undergo reassortment of their gene segments 
with each other due to infection of host with viruses of different subtypes and is referred to as 
antigenic shift. Such antigenic drift and shift in influenza A viruses, result in antigenically distinct 
variants that can be root cause of epidemics and pandemics outbreaks of varying severity.  
 
For influenza treatment, anti-viral drugs have shown limited effectiveness, as they need to be 
administered at early stage of infection and tend to slightly reduce the duration and symptoms of the 
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infection. Moreover, some strains have developed resistance against anti-viral drugs. Therefore, 
vaccination remains the most effective approach for controlling and preventing influenza. 
 
Table 2.1: Viral proteins of influenza A virus. Adapted from [222]. 
Segment  Name  Function 
1 PB2  
2 PB1  Polymerase complex. Viral replication  
3 PA    
4 HA Hemagglutinin, a glycosylated surface protein. Initiates infection by binding to 
cellular receptors. Antigenically hyper variable, 16 subtypes. 
5 NP Nucleoprotein, encapsidates the RNA segments. 
6 NA Neuraminidase, a glycosylated surface protein. Enzyme that splits off newly 
made virus from host cell. Antigenically variable, nine subtypes.  
7 M1 
 
M2 
Matrix protein. Located under the surface lipid layer. Antigenically very stable, 
but type-specific (A, B, C) 
Ion channel, just a few copies in the viral membrane. Antigenically very stable. 
8  
NS1 
NS2 
Non-structural proteins, functions not well understood.  
NS1 is assumed to inhibit the host’s interferon synthesis.  
NS2 helps in exporting the viral RNA complexed with NP to the cytoplasm. 
 
2.5.2 Vaccine strategies 
Numerous types of vaccines have been licensed and approved for use worldwide and some of them 
are in clinical and pre-clinical studies [224-226]. The licensed vaccines range from parenterally-
administered inactivated vaccines to intranasally-administered live-attenuated vaccines (LAIVs). 
Former ones are produced in either cultured eukaryotic cells or eggs while the latter are produced in 
embryonated eggs [227]. Inactivated influenza vaccine has been shown to generate HA-specific 
neutralization antibodies for providing immunity while LAIVs provide both humoral and cellular 
immunity. Vaccines based on these traditional approaches suffer from issues such as risk of 
reversion to their virulent state or limited duration of protection [34].  
 
Another approach focusses on subunit vaccines produced using recombinant proteins. HA, a major 
viral surface protein and target of host immune response during infection, is generally the active 
ingredient in such vaccines for the induction of protective neutralizing antibodies [228]. However, 
the HA protein is highly variable across the strains, thus antigenic mismatch due to mutating HA 
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can reduce the protective efficacy of that particular vaccine. These limitations have driven the need 
to develop a broadly-reactive, long-duration and cross-protective universal vaccine that can mitigate 
the phenomenon of antigenic shift and drift. The two main protein targets from the influenza virus 
for these vaccine development are derived from M2 and HA protein. HA has been shown to contain 
some conserved epitopes in its stalk region and broadly-neutralizing antibodies isolated from mice 
and human have been shown to recognise those epitopes in HA stalk [229]. 
 
One of the attractive universal vaccine targets is extracellular domain of Matrix 2 protein (M2e), 
which is derived from M2 protein of Influenza A. M2e consist of 23 amino acids, which are well 
conserved among influenza A viruses [230]. Due to small size of M2e and its close proximity to the 
membrane surface covered with relatively larger HA and NA, M2e is mostly hidden from the 
immune cells during natural infection and thus is not accessible to antibody [231]. Moreover, M2e 
alone has been shown to be a poor immunogen in its native form [230]. Since M2e is small in size 
and poorly immunogenic, several carrier system have been explored for M2e peptide to potentiate 
its immunogenicity including liposomes, viral vectors, virus-like particles [230, 232]. The 
protective efficacy of M2e-based vaccines is based on antibody-mediated cell cytotoxicity [233]. 
Several types of virus-like particles (VLPs) have been used to display M2e on its surface such as 
human papillomavirus [207], malva mosaic virus nanoparticles [234], papaya mosaic virus [235] 
and woodchuck hepatitis virus-like particles [236]. In a study, modularization of weakly 
immunogenic M2e into the microbially-produced MPyV VLP subunit has been shown to result in 
high immunogenic stimulation and protective efficacy [121, 203, 219]. Some of M2e-based 
influenza vaccines are in clinical studies and such vaccine candidates hold great promise to address 
the goal of universal influenza vaccine development. 
 
2.6 Group A streptococcus 
2.6.1 Disease and its global burden 
Group A streptococcus (GAS), also known as Streptococcus pyogenes, is an extracellular gram-
positive, non-motile bacterium that belongs to genus Streptococcus. Based on Lancefield 
classification scheme, beta-haemolytic streptococci can be classified into many groups depending 
on the antigenic differences in group-specific polysaccharides found on their cell walls [237]. There 
are more than 20 serologic groups identified and are denoted by letters (eg, A, B, C). Broad 
spectrum of diseases can be caused by GAS infections as shown in Table 2.2. Pharyngitis and 
impetigo associated with GAS causes highest absolute number of GAS infections each year. GAS 
bacteria can cause invasive infection even at distant sites (e.g. septic arthritis) in addition to local 
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sites (e.g. retropharyngeal abscess or necrotizing fasciitis). It can also result in streptococcal toxic 
shock syndrome as it produces group of superantigens and this disease has high fatality rate (>50%) 
[238]. In worst cases, it can cause chronic post-infectious sequelae diseases like acute rheumatic 
fever (ARF) and rheumatic heart disease (RHD). According to available data on the prevalence of 
RHD, it is predicted that over 300 million people are affected by RHD worldwide. These GAS 
diseases are highly endemic, mostly prevalent in developing countries and indigenous populations 
of developed countries [239]. 
 
 
Figure 2.8: 3D computer generated image of Group A streptococcus (GAS). Credit: U.S. Centers 
for Disease Control and Prevention. 
 
Antibiotic treatments are generally carried out to prevent ARF and RHD to avert recurrent 
infections with GAS which can trigger autoimmune responses. Secondary antibiotic prophylaxis is 
effective for those diagnosed with ARF, and can even prevent worsening of RHD, but the antibiotic 
treatment can be required for many years [240]. Such treatments are not feasible in especially poor 
developing countries which are most affected by GAS and its associated diseases. This makes a 
convincing case for the need of cost-effective vaccine strategies for control and prevention of 
primary GAS infection, which would prevent even its sequelae, including RF and RHD. 
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Table 2.2: GAS-associated diseases. Adapted from [241]. 
Noninvasive Invasive Postinfectious 
Pharyngitis Streptococcal toxic  
shock syndrome 
Rheumatic fever 
Pyoderma/impetigo  Necrotizing fasciitis Rheumatic heart disease 
Tonsillitis Septicaemia Poststreptococcal 
glomerulonephritis 
Scarlet fever Meningitis  
Otitis media Pneumonia  
Sinusitis Peritonitis  
Vaginitis Myositis  
 Osteomyelitis  
 Septic arthritis  
 Puerperal sepsis  
 Cellulitis  
 
2.6.2 Vaccine strategies 
Various strategies have been employed for developing potent vaccine against GAS infections. Due 
to the risk of induction of potential autoimmune response by GAS proteins, more efforts have been 
made for developing sub-unit based vaccines rather than traditional whole-cell based vaccines. 
Broadly, GAS vaccines can be divided into M-protein based and non-M-protein based vaccines. M-
protein, a cell-surface attached protein, is a major virulence factor in GAS infection [242, 243]. It is 
an -helical coiled-coil protein comprising three domains: a hypervariable A-repeat/ amino terminal 
domain, which defines GAS serotype (there are more than 100 GAS serotypes); a semi-variable B-
repeat domain (antibodies against this domain are non-opsonic) and a highly conserved C-repeat 
region (conserved between different strains with over 98% sequence identity) [242]. Two different 
strategies have been employed to develop broad-strain coverage vaccine based on M-protein 
subunits. One is based on N-terminal variable region (26-valent and 30-valent vaccines) while the 
other utilizes the antigens derived from the conserved C-terminal region (the J8 vaccine and the 
StreptInCor vaccine). 
 
The 26-valent and 30-valent M protein vaccines consist of recombinant peptides from N terminal of 
M-protein from several different serotypes of GAS. The 26-valent vaccine adjuvanted with alum 
underwent a phase I/II clinical human trial and was shown to be  immunogenic and generated 
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opsonizing antibodies against all serotypes of GAS in the vaccine [244]. To increase the coverage 
of circulating serotypes worldwide, 26-valent vaccine have been  reformulated into 30-valent 
vaccine, which not only induced opsonization antibodies against GAS serotypes present in the 
vaccine but also cross-opsonized a proportion of non-vaccine serotypes in preclinical study [245]. 
However, since dominant serotypes differ in different regions, it may result in a situation where 
vaccine, which provide good coverage of circulating strains of GAS in developed countries, can 
have limited coverage in many developing countries where GAS disease is endemic and vice versa 
[246]. 
 
Table 2.3: Peptide sequences of p145 and chimeric GAS M protein C-region peptides, J1-J9 and 
J14. Adapted from [247, 248]. 
p145     LRRDLDASREAKKQVEKALE 
J1     QLEDKVKQLRRDLDASREAKEELQDKVK 
J2                        LEDKVKQARRDLDASREAKKELQDKVKQ 
J3                          EDKVKQAERDLDASREAKKQLQDKVKQL 
J4                            DKVKQAEDDLDASREAKKQVQDKVKQLE 
J5                               KVKQAEDKLDASREAKKQVEDKVKQLED 
J6                                 VKQAEDKVDASREAKKQVEKKVKQLEDK 
J7                                   KQAEDKVKASREAKKQVEKAVKQLEDKV 
J8                                     QAEDKVKQSREAKKQVEKALKQLEDKVQ 
J9                                        AEDKVKQLREAKKQVEKALEQLEDKVQL 
J14                                  KQAEDKVKASREAKKQVEKALEQLEDKVK 
Peptides p145 and J1i to J9i and J14i are shown in black; flanking GCN4 sequences are shown in 
orange. 
 
In the other strategy, subunit antigens from the conserved C-repeat domain of the M protein were 
utilised. The development of a safe vaccine based on these conserved region necessitates the 
eradication of potentially human cross-reactive epitopes. Good and his co-workers tested 15 
synthetic peptides from the C region (20 amino acid long) in an epitope mapping study. p145, a -
helical peptide was shown to generate opsonizing antibodies against multiple GAS strains [249, 
250]. The minimal antibody epitopes were mapped from within this peptide and were referred to as 
J1i to J9i. Since p145 has a -helical confirmation, these peptides (J1i-J9i) were embedded within 
peptide sequence derived from GCN4 (a DNA-binding protein of yeast) to drive helical structure, 
so they can resemble the native helical conformation of p145. These peptides are shown in Table 
2.3. The chimeric peptides recognised by endemic human sera were J2, J7 and J8 [247], while J7 
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and J8 chimeric peptides were recognised by murine antisera [248]. Based on these studies, J8 was 
selected as the candidate as it contains the minimal B-cell epitope in conserved C-repeat domain of 
M-protein and doesn’t contain cross-reactive T cell epitope [248]. There has been different studies 
that have reported use of different delivery systems such as lipid core peptide system, VLPs and 
diphtheria toxoid for J8 antigen and evaluated their efficacy [241, 251]. A J8-diphtheria toxoid (J8-
DT) conjugate vaccine has successfully completed a human double-blinded Phase I pilot trial [252]. 
 
In a study, J8 peptide was modularized for presentation onto MPyV VP1 VLP and its subcutaneous 
delivery induced systemic opsonizing antibodies [210]. In the follow up study, intranasal delivery 
of modularized VLP carrying the J8 antigen induced high level of serum IgG and saliva IgA 
antibodies [253]. GAS colonization in the throats of intranasally-challenged mice was reduced and 
protection against lethal challenge was observed [253]. 
 
2.7 Non-parenteral delivery routes 
Non-parenteral routes of administration have been gaining attention as an alternative to traditional 
parenteral routes for vaccine delivery. It is important for diseases for which entry site of pathogens 
are mucosal surfaces and mucosal immunity is needed. These routes provide wide variety of 
advantages ranging from simpler needleless procedure to better patient compliance [254]. Non-
parenteral routes include oral, sublingual, topical, transdermal, ophthalmic, nasal, rectal, and 
vaginal routes. Characteristics of different sites for vaccine delivery in humans are discussed in 
Table 2.4. Intranasal administration is a promising option for local and systemic delivery and has 
been shown to be effective in various animal models and humans [255, 256]. Even then, its 
development has been hindered by issues associated with the requirement of delivery devices such 
as nebulizers [257] and reported neurotoxic side effects such as redirection of live-attenuated 
organisms or toxin-based adjuvants to the central nervous system upon intranasal immunization 
[258, 259]. Oral administration is the most commonly used form of non-parenteral route which is 
capable of inducing mucosal response in gastrointestinal tract but at the same time suffers from 
problems such as requirement of high doses, degradation of antigen by digestive enzymes and first-
pass metabolism effect [255]. Progress towards developing vaccines based on either oral or 
intranasal delivery has been hindered due to retraction of their live attenuated vaccines as adverse 
effects were observed [260]. 
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Table 2.4: Characteristics of different sites for vaccine delivery in humans. Mucosal immune 
responses (MIR) after immunization by different routes are indicated. Adapted from [261]. 
 Sublingual Buccal Oral/gastro-
intestinal 
Intranasal Pulmonary Dermal 
Estimated surface 
area 
(cm2) 
26.5 ± 4.2  50.2 ± 2.9 350,000a 160–180 700,000c 20,000 
 Epithelial structure 
(cell layers) 
Stratified 
squamous, 
non-
keratinized 
Stratified 
squamous, 
non-keratinized 
Simple 
columnar, 
non-ciliateda 
Pseudo-
stratified 
columnar, 
ciliated 
Pseudo-
stratifiedd/ 
Simple 
columnar, 
ciliatede 
Stratified 
squamous, 
keratinized 
Thickness, cell 
layer 
8–12 cells 
(0.1–0.2 mm) 
40–50 cells 
(0.5–0.8 mm) 
Single cell Single cell Single cell Multiple cells 
(2–3 mm) 
Vaccine target LCs (oral 
lymphoid foci) 
LCs (oral 
lymphoid foci) 
M cells (PP) M cells 
(NALT) 
M cells 
(BALT) 
LCs 
MIR distinct sites:       
Respiratory tract       
     Upper +++ ? − +++ ? +++ 
     Lower +++ ? − +/+++b ++ +++ 
Gastrointestinal 
tract 
      
     Stomach + ? + − ? ? 
     Small intestine +++ ? +++ − ? + 
     Colon ? ? ++ − ? + 
Reproductive tract +++ + − ++ ++ ? 
Systemic response +++ ++ + +++ + +++ 
Abbreviations used: MIR: mucosal immune response; LCs: Langerhans cells; MALT: mucosa-associated lymphoid 
tissue; PP: Peyer's patches; NALT: nasopharynx-associated lymphoid tissue; BALT: bronchus-associated lymphoid 
tissue. a Based on delivery in the small intestine, b Strong response by aerosol administration, c Total surface area lungs, 
d Epithelium lining the trachea, e Epithelium lining the bronchi.
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Oral mucosa including the buccal (the cheek lining) and sublingual (s.l.) (underside of the tongue), 
which are highly vascular, are the latest sites being explored for delivery of antigens since they 
allow their rapid absorption into the systemic circulation and avoid exposure to harsh gastric 
conditions [262]. Features such as high bioavailability and quick onset of action makes sublingual 
delivery a potential route for antigens that require induction of protective immunity in both systemic 
and mucosal immune compartments [263]. Many studies have demonstrated the efficacy of 
sublingual delivery for a variety of viral and bacterial antigens [264-266]. Song et al. showed that 
sublingual administration of inactivated influenza virus conferred protection against lethal viral 
challenge [264]. In another study, BenMohamed et al. showed that sublingual delivery of 
lipopeptides derived from Plasmodium falciparum induced strong systemic immune response in 
mice [266]. 
 
Most protein antigens are weakly immunogenic when administered via a mucosal route, which has 
necessitated the development of safe and potent mucosal adjuvants [264, 267]. Cholera toxin (CT) 
and E. coli heat-labile enterotoxin (LT) are commonly used mucosal adjuvants [264, 267]. They 
have been shown to potentiate the immune response but safety issues associated with them, makes 
them unsuitable for use in humans [260, 268]. Efforts have been made to alter these toxins to 
minimize their toxicity without compromising their adjuvanticity [269-271]. 
 
2.8 In vivo molecular imaging 
In vivo imaging has often aided in the understanding of mechanism of action of vaccine 
formulations [180, 272-274]. Different imaging systems can be categorized on the basis of 
attainable spatial resolution (macroscopic, microscopic or mesoscopic), source of energy for 
obtaining visual information (X-ray, photon, positron or sound waves) or kind of information 
acquired (anatomical, physiological, cellular or molecular) [275, 276]. Imaging systems such as 
computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission 
tomography (PET), single-photon-emission CT (SPECT), fluorescence reflectance imaging (FRI), 
fluorescence-mediated tomography (FMT) and bioluminescence imaging (BLI) have been utilized 
for clinical and preclinical use. Each of the these systems have their own advantages and 
disadvantages in terms of cost, complexity of operation, level of information and sensitivity [275, 
277]. Table 2.5 provides an overview of different imaging systems. 
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Table 2.5: Overview of imaging systems. Adapted from [275]. 
Technique Resolution* Depth Time† Quantitative
‡ 
Multi-
channel 
Imaging agents Target Cost*§ Main small-
animal use 
Clinical 
use 
MRI 10–100 μm No limit Minutes 
to hours 
Yes No Paramagnetic 
chelates, 
magnetic 
particles 
Anatomical, 
physiological, 
molecular 
$$$ Versatile 
imaging 
modality with 
high soft-tissue 
contrast 
Yes 
CT 50 μm No limit Minutes Yes No Iodinated 
molecules 
Anatomical, 
physiological 
$$ Imaging lungs 
and bone 
Yes 
Ultrasound 50 μm cm Seconds 
to 
minutes 
Yes No Micro-bubbles Anatomical, 
physiological 
$$ Vascular and 
interventional 
imaging|| 
Yes 
PET 1–2 mm No limit Minutes 
to hours 
Yes No 18F-, 64Cu- or 
11C-labelled 
compounds 
Physiological, 
molecular 
$$$ Versatile 
imaging 
modality with 
many 
tracers 
Yes 
SPECT 1–2 mm No limit Minutes 
to hours 
Yes No 99mTc- or 
111In-labelled 
compounds 
Physiological, 
molecular 
$$ Imaging labelled 
antibodies, 
proteins 
and peptides 
Yes 
FRI 2–3 mm <1 cm Seconds 
to 
minutes 
No Yes Photoproteins, 
fluorochromes 
Physiological, 
molecular 
$ Rapid screening 
of 
molecular events 
in 
surface-based 
disease 
Yes 
FMT 1 mm <10 cm Minutes 
to hours 
Yes Yes Near-infrared 
fluorochromes 
Physiological, 
molecular 
$$ Quantitative 
imaging of 
fluorochrome 
reporters 
In 
develop-
ment 
BLI Several 
mm 
cm Minutes No Yes Luciferins Molecular $$ Gene expression, 
cell 
and bacterium 
tracking 
No 
IM 1 μm <400– 
800 μm 
Seconds 
to hours 
No Yes Photoproteins, 
fluorochromes 
Anatomical, 
physiological, 
molecular 
$$$ All of the above 
at higher 
resolutions but 
limited 
depths and 
coverage 
In 
develop
ment# 
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*For high-resolution, small-animal imaging systems. (Clinical imaging systems differ.) †Time for image acquisition. 
‡Quantitative here means inherently quantitative. All approaches allow relative quantification. §Cost is based on 
purchase price of imaging systems in the United States: $, <US$100,000; $$, US$100,000–300,000; $$$, 
>US$300,000. ||Interventional means used for interventional procedures such as biopsies or injection of cells under 
ultrasound guidance. Laser scanning confocal or multiphoton microscopy. #For microendoscopy and skin imaging. IM: 
Intravital microscopy. 
 
Numerous molecular imaging techniques are being explored to understand the in vivo behaviour of 
biomaterials. These techniques allow investigation at whole-animal and tissue levels [278]. 
Particularly, fluorescence optical imaging has been one of the most rapidly adapted imaging 
technologies, owing to its versatility, affordability and simpler operation [276, 278]. Fluorescence 
imaging can be performed over long experimental times and is not restricted by issues such as half-
lives of radioisotopic PET tracers. Moreover, it allows experimentation with modular-laboratory 
designs [279]. Varieties of fluorescent probes such as dyes, fluorescent proteins and quantum dots 
can be employed for fluorescent imaging, which are either chemically conjugated or encapsulated 
within the imaging moiety. The technology has further evolved with the availability of highly 
sensitive detectors and efficient monochromatic light sources such as laser. These fluorescence 
imaging systems can be coupled with X-ray imaging system to provide anatomical information to 
augment the optical data. Despite these advantages, there are some downsides. For instance, optical 
signal is highly depth-dependant and suffers from tissue autofluorescence when visible light is the 
source of imaging. Fluorescence imaging in near-infrared (NIR) range of spectrum improves tissue 
penetration depth and detection sensitivity, in addition to reducing the inherent tissue 
autofluorescence and thus mitigates the shortcomings of optical imaging [280-282]. Moreover, 
semi-quantitative measurement of biodistribution can be obtained by ex vivo imaging of harvested 
organs and tissues, in addition to in vivo imaging of whole animal [276, 283]. 
 
NIR fluorescence imaging is based on the excitation of fluorescent probe by a source of photons, 
which is generally a light source with a specific bandwidth. Then the fluorescent probe in return 
emits a signal with specific spectral characteristics, which can be resolved with an emission filter 
and captured with a CCD camera [279]. It basically relies on the interaction of photons with the 
tissue components when it propagates through the tissue. There have been numerous reports 
describing successful in vivo NIR fluorescence imaging. In the field of vaccinology, it has been 
reported to track the complex antigen such as virus-like particles in vivo after immunization by 
different administration routes and in another study, model antigen ovalbumin was tracked in vivo 
for different vaccine formulations [180, 272]. These studies have demonstrated the capability of this 
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technology to aid in providing information regarding the biodistribution and clearance profile of the 
imaging moieties.  
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Chapter 3 
 
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-
dependent manner 
 
The entire Chapter 3 consists of the peer-reviewed journal article published as:  
 
Seth A, Ritchie FK, Wibowo N, Lua LHL, Middelberg APJ (2015). Non-carrier nanoparticles 
adjuvant modular protein vaccine in a particle-dependent manner. PloS One 10(3): e0117203.  
 
The following modifications were made to the article:  
− Page numbers of the original article were changed into the numbers consistent with those on 
the remainder of the thesis page numbers.  
− Figure numbers were changed into the numbers consistent with the remainder of figures in 
the thesis.  
− Section and sub-section numbers were changed into the numbers consistent with the 
remainder of sections and sub-sections in all chapters of the thesis.  
− The reference style of the original article was changed into the style consistently used in all 
chapters of the thesis. 
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3.1 Abstract 
Nanoparticles are increasingly used to adjuvant vaccine formulations due to their biocompatibility, 
ease of manufacture and the opportunity to tailor their size, shape, and physicochemical properties. 
The efficacy of similarly-sized silica (Si-OH), poly (D,L-lactic-co-glycolic acid) (PLGA) and poly 
caprolactone (PCL) nanoparticles (nps) to adjuvant recombinant capsomere presenting antigenic M2e 
modular peptide from Influenza A virus (CapM2e) was investigated in vivo. Formulation of CapM2e 
with Si-OH or PLGA nps significantly boosted the immunogenicity of modular capsomeres, even 
though CapM2e was not actively attached to the nanoparticles prior to injection (i.e., formulation was 
by simple mixing). In contrast, PCL nps showed no significant adjuvant effect using this simple-
mixing approach. The immune response induced by CapM2e alone or formulated with nps was 
antibody-biased with very high antigen-specific antibody titer and less than 20 cells per million 
splenocytes secreting interferon gamma. Modification of silica nanoparticle surface properties 
through amine functionalization and pegylation did not lead to significant changes in immune 
response. This study confirms that simple mixing-based formulation can lead to effective adjuvanting 
of antigenic protein, though with antibody titer dependent on nanoparticle physicochemical 
properties. 
 
3.2 Introduction 
Vaccination has proved to be one of the most influential developments in human health history. Over 
years, vaccination has been based on live attenuated organisms, killed organisms or inactivated 
toxins. However, vaccines based on these traditional approaches suffer from problems including 
reversion to their virulent state or limited duration of protection [1, 2]. These limitations have led to 
shifting of interest towards recombinant proteins such as subunit vaccines, based on a specific portion 
of the pathogen. Subunit vaccines are being preferred over attenuated live or inactivated whole 
organism vaccines as they are generally well purified and characterized, hence have improved safety 
profile and are easier to scale up over the latter. Despite the advantages of subunit vaccines, there are 
some downsides. For instance, usually antigen by itself is weakly immunogenic, which necessitates 
use of an adjuvant in formulation [2]. Selection of a suitable adjuvant is necessary to maintain balance 
between the upside enhancement of immunogenicity and the downside risk of side effects. In addition 
to enhancing immunogenicity, adjuvants can be employed to reduce the dosage or number of doses 
required for protective immunity.  
 
In recent years, nanoparticles have attracted tremendous interest as a component within experimental 
vaccine formulations [3]. The use of nanoparticles in vaccinology is inspired by the fact that most 
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pathogens have a dimension within the nano-size range [4], and therefore can be processed efficiently 
by the immune system, leading to a potent immune response. Nanoparticles are therefore being 
exploited to elicit desired immune responses for both prophylactic and therapeutic effects. They are 
utilized as either delivery systems to enhance antigen processing or to protect antigen from premature 
degradation, and/or as an immunostimulant to trigger immune response [5]. Nanotechnology allows 
customization of the properties of nanoparticles such as size, shape and surface charge to meet 
application requirements, resulting in a great variety of nanoparticles. A variety of biological as well 
as synthetic nanoparticles have been approved for human use [6-8], and many more are in clinical or 
pre-clinical studies [2, 9]. Conventionally, the use of nanoparticles as a component in vaccine 
formulations is predicated on an assumed requirement for association between the antigen and 
nanoparticle components, to gain an adjuvanting effect [10, 11]. This association between 
nanoparticles and antigen usually involves attachment either by conjugation, adsorption or 
encapsulation. However, a recent study has shown that it is possible to achieve an adjuvanting effect 
by simple mixing of nanoparticles and a sub-unit protein antigen from a virus-like particle, termed a 
capsomere, that has viral molecular architecture, which is being used in this study [12]. 
 
Virus-like particles (VLPs) are now a well-established vaccine class [6, 13, 14]. Modularized VLPs 
are emerging that allow design for efficacy against diseases different to the parent VLP through 
presentation of appropriate antigenic peptide modules within the VLP structure. VLPs are excellent 
vaccines as they are self-adjuvanting due to their particle characteristics and highly 
immunostimulatory because of their repetitive molecular structures [14-17]. Recent studies on the 
VLP-forming protein VP1 from murine polyomavirus (MPyV) demonstrate that use of the sub-unit 
capsomere, the basic building block of a VLP, can lead to high immunogenic stimulation and 
protective efficacy with an otherwise immunologically weak peptide, M2e from influenza [12, 18, 
19]. Studies using capsomeres based on papillomavirus [20], human respiratory syncytial virus [21] 
and human mucin-1 cancer antigen [22] also confirm that capsomeres are an emerging and interesting 
vaccine platform, which may retain the molecular activating signals of viruses but with some 
advantages including improved stability [23-25], tolerance to antigen incorporation [26] and 
simplified manufacture [18, 27]. However, as capsomeres do not possess the particle structure of the 
VLP, formulation with adjuvant may be necessary, whereas good quality VLPs do not require 
adjuvant [18]. In this context, nanoparticles prove an interesting adjuvant class, as their addition to 
the vaccine formulation reintroduces the particle component that is inherent in VLPs but lacking in 
capsomeres, while the capsomere possesses appropriate and immunostimulatory molecular repetition. 
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Silica based nanoparticles are widely considered as being biocompatible, are non-toxic and possess 
flexible surface chemistry. These features make them attractive candidates for application in a vaccine 
system. Biodegradability is an important feature, which improves the safety profile of the 
formulation. PLGA and PCL are two of the most commonly used biodegradable and biocompatible 
polymers [2, 28]. In particular, PLGA nps owing to their clinical approval and long safety record, 
have been widely explored and employed to develop nano-vaccines for a variety of antigens [29-32]. 
PCL is more hydrophobic and has a slower degradation profile as compared to PLGA [33].  
 
A major goal of the work presented here was to understand, using in vivo tests, the impact of 
nanoparticle properties on their efficacy as non-carrier adjuvants for a modular capsomere sub-unit 
protein antigen. PEG-coated PLGA and PCL nps were synthesized by emulsion solvent evaporation. 
Highly monodisperse and spherical nps were prepared. Inorganic silica nps were obtained 
commercially. Viral modular capsomeres presenting M2e antigen were synthesized in a microbial 
expression system [19], and were formulated with the varied nps by simple mixing. The effects of 
varying the surface charge of silica nps on their adjuvanting activity, as well as the impact of selective 
PEGylation, were also investigated. 
 
3.3 Materials and Methods 
3.3.1 Materials 
Poly (D,L-lactic-co-glycolic acid) (PLGA, D,L-lactide:glycolide = 65:35, M.W. 40000-75000), 
polycaprolactone (PCL, Mn 70000-90000), (3-aminopropyl) triethoxysilane (APTES), o-
phenylenediamine dihydrochloride, phosphate citrate buffer and HRP-conjugated goat anti-mouse 
IgG1 and IgG2a were purchased from Sigma-Aldrich (St Louis, MI) and used as supplied. 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene-glycol)-2000] (PEGPE) 
was purchased from Avanti (Alabaster, AL). Polyethylene glycol succinimidyl ester (mPEG-NSH; 
MW 5000) was purchased from Nanocs (New York, NY). Biotinylated M2e peptide was purchased 
from Peptide 2.0 Inc. (Chantilly, VA). Sodium chloride (NaCl), potassium chloride (KCl), disodium 
hydrogen phosphate (Na2HPO4), potassium dihydrogen phosphate (KH2PO4), Tween 20 and 
chloroform were obtained from Chem-supply (Gillman, SA, Australia) and used as supplied. 
 
3.3.2 Protein expression and purification 
Expression vectors for GST-tagged CapM2e (capsomere presenting M2e) and GST-tagged wt Cap 
(capsomere without M2e insert) were as described previously [18, 19]. Expression vector was 
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transformed into chemically competent E. coli Rosetta (DE3) pLysS cells (Novagen, Madison, WI). 
GST-tagged CapM2e and GST-tagged wt Cap were expressed and purified to give low-endotoxin (< 
2 EU mL-1) CapM2e and wt Cap capsomeres, respectively, as previously described [19]. Endotoxin 
removal from GST-tagged CapM2e was performed by phase separation using Triton® X-114 (X114, 
Sigma-Aldrich, USA) as previously described [19]. Endotoxin removal from wt Cap was performed 
by using an anion exchanger, a Vivapure Q Mini M spin column (Sartorius Stedim, France) as 
previously described [18]. Capsomere protein concentration was adjusted to 0.75 mg mL-1 with 
endotoxin-free PBS, and endotoxin content tested to be < 2 EU mL-1. Endotoxin level was analysed 
using LAL-based assay Endosafe PTS®-2005 (Charles River Laboratories, Wilmington, MA). 
CapM2e and wt Cap capsomeres were aliquoted and stored in -80°C until further use.  
 
3.3.3 Adjuvant preparation 
All adjuvant preparations were conducted in endotoxin free environment.  
3.3.3.1 Synthesis of PLGA and PCL nanoparticles 
PLGA and PCL nps were prepared by an oil-in-water (o/w) emulsion solvent evaporation method as 
described previously [34]. Briefly, 400 µl of mixture of PLGA or PCL (4 mg) and PEGPE (8 mg) in 
chloroform was added dropwise into 4 ml water. Then the solution was sonicated at 10 W (Branson 
Sonifier 450 microtip probe ultrasonicator, Danbury, CT, USA) for four 25s bursts interspersed with 
cooling on an ice bath for 60s. The chloroform was separated from the emulsified solution by using 
a rotary evaporator (Rotavapor R-215, Büchi, Postfach, Switzerland). Nanoparticles were washed 
three times by centrifugation (18000 g, 5 mins) using Amicon ultra centrifugal filter devices 
(Millipore, Billerica, MA, USA) to remove free PEGPE. Endotoxin level in PLGA and PCL nps were 
analyzed using LAL-based assay Endosafe PTS®-2005 (Charles River Laboratories, Wilmington, 
MA) and were found to be < 2.5 EU mL-1. 
 
3.3.3.2 Silica nanoparticle preparation 
Commercial silica nps of nominal diameter 50 nm (Cat. 24040, Polysciences Inc., Warrington, PA) 
were dialyzed using snake-skin® pleated dialysis membrane (nominal molecular weight cut-off of 
10kDa; Thermo Scientific, Rockford, IL, USA) against PBS at 4°C for 24 h and adjusted to a nominal 
(based on the product label) silica concentration of 2 mg mL-1 with PBS. Endotoxin level in silica nps 
was analyzed using LAL-based assay Endosafe PTS®-2005 (Charles River Laboratories, Wilmington, 
MA) and was found to be < 2 EU mL-1. 
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3.3.3.3 Silica nanoparticles amine functionalization 
Amine-functionalized silica nanoparticles (Si-NH2 nps) was prepared according to literature with 
some modification [35]. Commercial silica nps as above were dialyzed against Milli Q water at 4°C 
for 24 h and adjusted to a nominal silica concentration of 30 mg mL-1 with Milli Q water. Then, 
nanoparticle solution was subjected to centrifugal wash (18000 g, 20 mins) with absolute ethanol 
three times, followed by sonication (Branson Ultrasonics Corporation, Danbury, CT) at output 30 for 
4 cycles of 20s to re-suspend in ethanol. Nanoparticle solution in absolute ethanol was incubated with 
14% (v/v) (3-aminopropyl) triethoxysilane (APTES; Cat. A3648, Sigma-Aldrich, St Louis, MA) for 
3h with constant stirring. After incubation, nanoparticle-APTES solution was subjected to centrifugal 
washing (18000 g, 20 mins) with absolute ethanol three times, followed by sonication to finally re-
suspend in absolute ethanol. Then, amine functionalized nps were dialyzed against Milli Q water at 
4°C for 24h and adjusted to a concentration of 2 mg mL-1 with Milli Q water. Endotoxin levels in 
amine-functionalized silica nps was analyzed using a LAL-based assay Endosafe PTS®-2005 
(Charles River Laboratories, Wilmington, MA) and was found to be < 2 EU mL-1. 
 
3.3.3.4 Silica nanoparticles PEGylation 
Pegylated silica nanoparticles (Si-PEG nps) were prepared by adding polyethylene glycol 
succinimidyl ester (mPEG-NSH; MW 5000, PDI <1.08, purity >95%, Cat. PG1-SC-5k, Nanocs Inc) 
into 3.4 mg mL-1 Si-NH2 nps in 2:1 (mPEG-NSH:Si-NH2) molar ratio in an endotoxin-free 
environment. The mixture was stirred at room temperature for 2 h. Endotoxin level in pegylated silica 
nps was analyzed using LAL-based assay Endosafe PTS®-2005 (Charles River Laboratories, 
Wilmington, MA) and was found to be < 2 EU mL-1. 
 
3.3.4 Characterization of nanoparticles  
3.3.4.1 Dynamic light scattering and zeta potential measurement  
The hydrodynamic diameter and surface charge (zeta potential) of nanoparticle solutions were 
measured with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) using dynamic light 
scattering (DLS) and electrophoretic light scattering (ELS), respectively. This instrument employed 
a 633 nm laser wavelength at a scattering angle of 173° and 4 mW He-Ne laser power. For dynamic 
light scattering (DLS), nanoparticles were diluted 100-fold with water to avoid multiple scattering 
effects. Refractive index and viscosity of water were assumed to be 1.33 and 0.89 cP, respectively. 
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3.3.4.2 Transmission electron microscopy (TEM) measurement 
Two microliters of each sample (1 mg mL-1) was applied onto 200-mesh carbon-coated grids 
(Proscitech, Brisbane, QLD, Australia). Remaining liquid on the grids was blotted with filter paper 
after 2 min, and grids were washed with water, stained with 1% (w/v) uranyl acetate for 1 min and 
then allowed to air-dry prior to observation with a Jeol 1011 (Jeol Ltd., Tokyo, Japan) microscope at 
100 kV accelerating voltage. Electron micrographs were recorded digitally using a side-mounted 
Morada camera (Olympus-Soft Imaging System GmbH, Münster, Germany) with iTEM software 
(version 3.2, Soft Imaging System GmbH). 
 
3.3.5 Adsorption studies 
50 µg of nanoparticle solution (Si-OH, Si-NH2, Si-PEG, PLGA or PCL nps) in PBS was mixed with 
15 µg of CapM2e solution in PBS at room temperature. All tubes were centrifuged at 22000g, 4°C 
for 20 min. Supernatant was carefully removed and protein concentration was determined by high 
performance liquid chromatography (HPLC) analysis as described previously [36]. 
 
3.3.6 Immunization 
Two biological studies were conducted. In the first study, six groups of five female BALB/c mice 
(Animal Resources Centre, WA, Australia) were immunized with 15 g capsomere without M2e 
inserted (wt Cap) or CapM2e, alone or adjuvanted with 50 g of Si-OH or PLGA or PCL nps. M2e 
peptide adjuvanted with Si-OH nps was used as control group. Adjuvanted CapM2e was prepared by 
mixing 15 µg CapM2e with 50 µg of selected adjuvant shortly prior to injection. Three subcutaneous 
immunizations were given on days 0, 21 and 42. Blood samples were taken by tail snip before the 
first immunization (day 0), followed by eye bleeds on days 14 and 35. Final blood sample was 
collected on day 56 by heart puncture. All animal experimental work was reviewed and approved by 
The University of Queensland Animal Ethics Committee (AEC Approval Number: 
AIBN/058/13/NIRAP/SMART FUTURES). All animals were cared for humanely in accordance with 
the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
In the second study, four groups of five female BALB/c mice (Animal Resources Centre, WA, 
Australia) were immunized with 3 µg M2e peptide adjuvanted with 50 µg of Si-OH nps or 15 µg 
CapM2e adjuvanted with 50 µg of Si-OH or Si-NH2 or Si-PEG nps. The immunization regime was 
same as that in the first study. All animal experimental work was reviewed and approved by The 
University of Queensland Animal Ethics Committee (AEC Approval Number: 
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AIBN/189/12/NIRAP/SMART FUTURES). All animals were cared for humanely in accordance with 
the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
 
3.3.7 Enzyme-linked immunosorbent assay (ELISA) 
Pierce® Streptavidin High Binding Capacity (Thermo Fisher Scientific, Waltham, MA) coated plates 
were washed 3 times with PBST (137 mM NaCl, 2.7 mM KCl, 10.15 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4, 0.05% (v/v) Tween 20). Biotinylated M2e peptide (Peptide 2.0 Inc., Chantilly, VA) 
at 10 mg mL-1 in PBS was adsorbed to the plates, 100 µL per well for 2 h at room temperature. Plates 
were then washed 3 times with PBST. Plates were incubated with mouse sera initially at 100-fold 
dilution followed by four-fold serial dilutions with PBST containing 0.5% (w/v) skim milk (90 min, 
37°C). After washing 4 times with PBST, HRP-conjugated goat anti-mouse IgG1 or IgG2a (Ab97240 
or Ab97245, respectively, Abcam, Cambridge, UK) was added at 20 000- or 10 000-fold dilution, 
respectively, followed by incubation (90 min, 37°C). Plates were washed 4 times with PBST and 
developed (0.4 mg mL-1 o-phenylenediamine dihydrochloride (Sigma-Aldrich, St Louis, MA), 50 
mM phosphate citrate buffer containing 0.03% (w/v) sodium perborate) prior to absorbance 
measurement at 450 nm. End point titers were determined as the highest dilution of serum for which 
the OD was 3 standard deviations above the mean optical density of blank wells. 
 
3.3.8 Enzyme-linked immunospot (ELISPOT) 
IFN-γ ELISPOT was performed as described previously [37]. Briefly, 14 days after final 
immunization, splenocytes were restimulated in vitro in the presence or absence of M2e peptide. The 
number of spots of cells secreting IFN-γ was counted to assess the frequency of M2e-specific 
cytotoxic T-cells. Concanavalin A (Con A) was used as non-specific positive control.  
 
3.3.9 Statistical analysis  
Statistical analysis was performed using GraphPad Prism Version 5.03 (GraphPad Software Inc., 
USA). Comparison of more than two groups was performed with the Tukey’s multiple comparison 
tests. Comparison between two groups was performed with t test. p < 0.05 was considered statistically 
significant. 
 
3.4 Results and Discussion 
The adjuvanting efficacy of similarly-sized nanoparticles having different properties was investigated 
in in vivo immunogenicity studies, particularly in their roles to adjuvant modular capsomeres. 
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Modular capsomere presenting antigenic M2e peptide from Influenza A virus (CapM2e) was 
synthesized as described previously [12, 18, 19]. Formulations of CapM2e with nanoparticles were 
made by simple mixing prior to injection.  
 
In the first study, adjuvanting efficacy of nanoparticles made of three different materials, 
biocompatible inorganic silica (Si-OH), biodegradable poly (lactic-co-glycolic acid) (PLGA) and 
polycaprolactone (PCL), were studied. Biocompatible inorganic solid silica nanoparticles were 
obtained commercially, whereas PLGA and PCL nanoparticles were prepared using an oil-in-water 
(o/w) emulsion solvent evaporation method by employing PEGPE as the oily emulsifier during the 
process, as described [34]. The size of PEG-coated biodegradable nanoparticles could be controlled 
by varying the ratio of polymer to the oily emulsifier and also by varying sonication conditions. 
 
Figure 3.1 shows the transmission electron micrographs (TEM) of Si-OH, PLGA, and PCL 
nanoparticles, revealing the spherical morphology of each type of nanoparticle. The average size of 
nanoparticles as observed from TEM is presented in Table 3.1. TEM images show that PLGA and 
PCL nanoparticles were more polydispersed as compared to Si-OH nanoparticles. Nanoparticle size 
was also determined using dynamic light scattering (DLS) analysis (Table 3.1), which gave a slightly 
larger size in comparison to TEM measurement. TEM gives information about size and surface 
morphology (i.e., shape and surface structure of individual nanoparticles) in a dried state while DLS 
measures the hydrodynamic diameter of particles in solution. This hydrodynamic diameter is larger 
than the actual dried diameter as it also takes into account any associated hydration layer as well as 
adsorbed organic stabilizers if present. Interpretation is also dependent on solution parameters 
including viscosity used to estimate the Stokes diameter in DLS.  
 
Previous studies have shown that 50 nm non-carrier nps can strongly adjuvant the viral sub-unit 
capsomere antigen, even in the absence of  significant association between nanoparticles and antigen 
[12]. In the present study, since both CapM2e (isoelectric point pI=4.9) [38] and Si-OH nanoparticle 
(Zeta potential= -41.3 mV) carry net negative charge at physiological pH, significant interaction 
between them was not expected and indeed was not found in previous studies [12]. Significant 
association between PLGA and PCL nps with CapM2e was also not expected as each np type includes 
polyethylene glycol (PEG) chains that will locate to the np surface and provide for low protein-
binding character [39, 40]. This expectation was confirmed by determining the extent of adsorption 
of these CapM2e onto these three sets of nanoparticles (Figure 3.2). 
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Figure 3.1: Hydrodynamic size distribution and TEM images of nanoparticles A) silica, B) 
PLGA, C) PCL, D) amine functionalized silica and E) pegylated silica. Scale bar is 100 nm. 
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Table 3.1: Characteristics of different nanoparticles. 
Nanoparticles Size (dh. nm)±S.D. 
(DLS) 
Polydispersity 
Index (PDI) 
Size (dt.nm) 
(TEM) 
Silica nanoparticles (Si-OH) 81±2.3 nm 0.076 50 nm 
PLGA nanoparticles (Poly(D,L-
lactide-co-glycolide) 
88±1.8 nm 0.130 40-60 nm 
PCL nanoparticles (Poly 
caprolactone) 
87±1.5 nm 0.240 40-70 nm 
S.D.- Standard deviation, dh-hydrodynamic diameter  
 
 
Figure 3.2: Percentage of protein mass (CapM2e) in supernatant after mixing with different 
nanoparticle solutions. 
 
Figure 3.3 shows the endpoint titer of anti-M2e specific total IgG, IgG1, and IgG2a in BALB/c mice 
after three subcutaneous immunizations with different formulations. Capsomere without M2e 
inserted (wt Cap) was injected as a negative control and, as expected, induced very low M2e-specific 
antibodies. A similar result was observed for the negative-control formulation of M2e peptide with 
Si-OH nps which also did not induce a specific anti-M2e immune response, confirming the low 
immunogenicity of this peptide sub-unit antigen. CapM2e without adjuvant induced a 104 antibody  
titer, consistent with results observed earlier [19], revealing a significant effect of modularizing the 
weakly immunogenic peptide M2e into the molecular viral architecture provided by the capsomere, 
even in the absence of a particle adjuvant. Figure 3.3A shows that the immunogenicity of CapM2e 
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was boosted significantly, more than ten-fold, when formulated with Si-OH or PLGA nps. This 
adjuvanting effect however was not observed when CapM2e was formulated with PCL nps. PCL has 
a higher hydrophobicity and slower degradation profile in comparison to PLGA [41]. A number of 
studies have demonstrated that the hydrophobicity of nanoparticles could affect the overall 
immunogenicity of antigens [42-44]. Hence, the hydrophobic properties of PCL might affect the 
interaction of PCL with the cells of the immune system or with the modular capsomere which could 
then affect the mechanisms of antigen processing. It is interesting to observe that two biodegradable 
nanoparticles with different biodegradation profiles have very different effects on boosting (or not) 
the immune response of antigen. 
 
Figures 3.3B and C show the anti-M2e specific IgG1 and IgG2a titers of immunized mice that 
correlate to Th2 (humoral-biased) and Th1 (cellular-biased) responses, respectively. The high IgG1 
and low IgG2a titers reveal a Th2- biased immune response to capsomeres with as well as without 
nanoparticles. This observation is unsurprising as BALB/c mice are known to develop antibody-
predominant immune responses [45]. Further study using Th1-skewed mouse strains, such as 
C57BL/6, would be needed to confirm whether Th2-biased immune responses observed here was due 
to the mouse strain used in this study, the antigen, or the formulation of CapM2e-nps. Other published 
studies related to M2e also resulted in an antibody-predominant immune response [46, 47], while 
only a few studies have reported cellular response [48, 49]. This observation was further confirmed 
by ELISPOT assay results (Figure 3.4) which show a minimum number of cells secreting interferon 
gamma (IFN-γ). ELISPOT assay for other cytokines such as IL-4 can be carried out in a future study 
to provide complimentary information on induced antibody response such as frequency of antibody-
secreting cells. 
 
Formulation of CapM2e with Si-OH nps induced the highest antibody titer in comparison to other 
formulations. Therefore, further study was conducted on Si-OH np variants, to reveal the effects of 
different surface properties on adjuvanting efficacy. Silica nanoparticles, inherently, have a 
negatively-charged surface due to the presence of silanol groups. To introduce positive charges on 
the surface of Si-OH, (3aminopropyl) triethoxysilane (APTES) was coated on the surface of Si-OH 
through formation of siloxane bonds by reacting with silanol hydroxyl groups. Si-NH2 was further 
modified to shield the surface charge by conjugation of polyethylene glycol (PEG). This charge 
transition on the surface of nanoparticles was assessed with zeta potential measurement, as presented 
in Table 3.2. The unmodified Si-OH nps showed an average zeta potential of -41.3 mV, which shifted 
to +44.5 mV after modification with APTES (Si-NH2). The zeta potential of Si-NH2 nps was reduced 
after conjugation with PEG derivative (+3.41 mV) which indicates overall surface coverage of 
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nanoparticles by PEG chains. There was an increase in the size of nps after each modification step 
(Table 3.2).  
 
Figure 3.3: M2e-specific antibody titers in BALB/c mice following three subcutaneous 
immunizations with different formulations. A) Total IgG, B) IgG1, and C) IgG2a. *, p<0.05; **, 
p<0.01; ***, p<0.001; ns=not significant. 
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Table 3.2: Characteristics of silica nanoparticles with different surface properties 
Nanoparticles  Size 
(dh.nm)±S.D. 
(DLS) 
Polydispersity 
Index (PDI) 
Zeta Potential 
(mV) 
Silica nanoparticles (Si-OH) 81±2.3 nm 0.076 -41±2.1 mV 
Silica nanoparticles with amine 
functionalization (Si-NH2) 
103±2.7 nm 0.049 +45±1.4 mV 
PEG-coated silica nanoparticles with 
amine functionalization (Si-PEG) 
129±1.9 nm 0.130 +3.4±0.5 mV 
S.D.- Standard deviation, dh-hydrodynamic diameter  
 
 
Figure 3.4: Determination of IFNγ response in splenocytes. M2e-specific T-cell response was 
evaluated by measuring IFNγ secreting cells by enzyme-linked immunospot (ELISPOT). A) Carrier 
(wt VP1)-specific, B) M2e-specific, C) positive control (Concanavalin A (Con A)). No significant 
difference was observed between the mean value of each group (p>0.05). 
 
Figure 3.5 shows the endpoint titer of anti-M2e specific IgG1 in mice after three subcutaneous 
immunizations with different formulations. No significant differences in immune response between 
different nanoparticle formulations with negative, positive and neutral surface charges could be 
observed statistically as these different groups were compared by one-way ANOVA followed by 
Tukey’s multiple comparison. Studies have reported that nanoparticle physicochemical properties 
including size [10, 50], shape [51, 52], surface charge [53, 54] and hydrophobicity [43] influence the 
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interaction of nanoparticles with the immune system [42]. Several in vivo studies have  reported that 
surface charge of nanoparticles affects the immune response of formulations [55, 56]. However, 
Foged and co-workers reported no effect of surface charge of nanoparticles of similar sizes on their 
uptake by dendritic cells (DCs) [53]. In this present study, the immune response might already be at 
its maximum and thus no further boosting of immunogenicity of formulation could be observed on 
changing the surface charge of nanoparticles. Further study is needed to fully explore and 
mechanistically understand these effects, for different antigen classes, and represents ongoing work 
in our laboratory. 
 
 
Figure 3.5: M2e-specific IgG1 titer in BALB/c mice following three subcutaneous immunizations 
with different formulations. *, p<0.05; **, p<0.01; ***, p<0.001; ns=not significant. 
 
This study explored the potential of various nanoparticles as a non-carrier adjuvant to modular 
capsomere, in contrast to a conventional attachment approach which involves loading of antigen 
either on the particle surface by chemical conjugation or physical adsorption or within the particle by 
encapsulation or entrapment. This non-attachment approach is increasingly being investigated [12, 
57] particularly as it offers much simpler formulation by mixing. Wibowo et.al [12] showed that non-
carrier silica nanoparticles significantly boosted the immunogenicity of a subunit antigen even in the 
absence of significant association between these two components. However, a study by Zhang et al. 
[57] did not show enhanced IgG response by simple mixing. This difference is perhaps due to the 
absence of PAMPs in the OVA antigen that they used in comparison to viral capsomere used in the 
study by Wibowo et al. [12]. The presence of PAMPs in viral capsomere can act as danger signals 
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that activate pattern recognition receptors on cells of the immune system [58]. Also, the difference in 
immunogenicity might be due to particle size (500 nm in Zhang et al. study, 50 nm in Wibowo et al.). 
Wibowo et al. clearly showed the striking effect of silica particle size on the adjuvanting efficacy, 
where boosting of immune response was observed for 50 nm sized silica nanoparticles but not for the 
larger (1000 nm) counterpart. Other studies have shown that size of particles is critical for their 
adjuvanting activity [10, 59, 60]. Nevertheless, Zhang et al. demonstrated that the addition of non-
attached formulation to a nanoparticle-encapsulated antigen formulation enhanced antigen-specific 
IgG level and avidity, as well as increased cytokine secretion and memory T cell generation [57], 
highlighting the potential of nanoparticles as a non-carrier adjuvant class.  
 
In this study, the various nanoparticles used have similar size but different physicochemical 
characteristics. The results demonstrated the superiority of silica nanoparticle in comparison to PLGA 
and PCL, possibly due to the ability of silica nanoparticles to induce several immunostimulatory 
cytokines, such as IFN, IL-4 and IL-3 [61], or possibly because PLGA and PCL nanoparticles were 
not at their optimal size. Yan et al. [60] reported size-dependent adjuvanting effects for different 
particle types, and found that there exists an optimum size range for maximum adjuvanting efficacy 
for each type of particle.  
 
This study further demonstrates the potential of the modular capsomere as a vaccine platform, as 
shown in previous studies [12, 18, 19]. A significant effect of modularizing the weakly immunogenic 
M2e antigen into the molecular viral architecture of a capsomere on immunogenicity was observed, 
suggesting that even in the absence of particle stimulation, capsomeres still retain the molecular 
activating signals of viruses. Moreover, nanoparticles can further enhance capsomere 
immunogenicity by introducing the particle component which is lacking in the capsomere structure. 
The low amount of endotoxin presence in the formulation suggests that the immunogenicity observed 
was not due to the bacterial signals. This two-component formulation prepared by simple mixing can 
potentially activate the immune system through two different pathways, leading to the observed 
strong immune response. This simple mixing approach, by eliminating the complexity of antigen 
conjugation or incorporation, may simplify approaches for the preparation of safe and efficacious 
nanoparticle-containing vaccines, though in a fashion that is nanoparticle and probably antigen 
specific. 
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3.5 Conclusion 
This study investigated the effects of composition and surface properties of non-carrier nanoparticles 
on their adjuvanting efficacy for modular capsomeres presenting influenza M2e antigen (CapM2e). 
Our findings showed that Si-OH and PLGA nps could boost the immunogenicity of these capsomeres, 
with the immune response being predominantly antibody biased and close to the maximum expected. 
It was observed that there was no significant difference on adjuvanting effect of Si-OH nps after 
varying their surface properties. Induction of maximal immune response by these nanoparticle 
adjuvanted modular capsomere formulations is attributed to combined synergistic effects of viral 
molecular and particle signals contributed by the capsomere protein and nanoparticle components, 
respectively. This simple mixed formulation of subunit antigen (capsomere) augmented with 
nanoparticles can prove to be a more robust formulation than for simpler antigens where in the 
absence of viral molecular signal, the properties of the adjuvant particle may become more critical. 
Understanding the mechanism of action of these formulations through further studies will be 
important for accelerating the rational design of nanoparticle-containing vaccines. 
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Chapter 4 
 
In vivo trafficking of a mixed nanoparticle and modular virus-like particle 
subunit vaccine formulation 
 
4.1 Abstract  
Nanotechnology is opening new avenues in vaccinology through the development of nanoparticle-
based adjuvants. We have previously shown the adjuvanting efficacy of non-carrier nano-sized silica 
particles on modular virus-like particle subunits presenting M2e from Influenza A virus (CapM2e) 
which was not observed by their micro-sized counterparts. Here, we visualized the in vivo trafficking 
of CapM2e alone and when formulated with silica nano- and micro-sized particles in mice after 
subcutaneous immunization to have a better understanding of the effect of biodistribution on their 
resultant immune response. CapM2e and adjuvant particles seem to remain at the injection site for up 
to 24 h although their concentration decreased with time. CapM2e traffic into inguinal lymph nodes 
which could have contributed to the high immunogenicity of CapM2e, even without adjuvant. On the 
other hand, adjuvant particles traffic into the gastrointestinal tract including stomach and intestines, 
showing that adjuvant particles traffic separately from CapM2e. Ex vivo fluorescence analysis of 
these organs confirmed these in vivo observations. Microparticles cleared faster than their 
nanoparticle counterparts. These results lead us to the hypothesis that nanoparticles may be 
influencing the uptake process of CapM2e at the injection site. 
 
4.2 Introduction 
Virus-like particles (VLPs) are a versatile class of vaccine, which have been used as parental vaccine, 
and also have been designed as modular VLPs having efficacy against diseases different to the parent 
VLP through incorporation of antigenic modules within the VLP structure [1-3]. Commercial success 
of VLPs is well demonstrated by the availability of VLP-based vaccines for cervical cancer and 
hepatitis B in the market [3]. VLPs comprise building units of pentameric capsomeres, which are 
formed by assembly of capsid proteins. These capsomeres themselves are being explored as an 
emerging class of vaccine. The modular capsomeres provide some advantages including simplified 
bio-manufacturing [4, 5], as they self-assemble inside a microbial expression system, as well as 
improved stability [6-8] and better tolerance to antigen insertion [9]. Recent studies on capsomere 
vaccination have demonstrated the potential of this new subclass of subunit vaccines through 
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presentation of antigen derived from Influenza A virus [5, 10], Group A Streptococcus (GAS) [11], 
human syncytial virus [12], and human mucin-1 cancer [13]. However some studies have shown that, 
since capsomeres lack the particle structure of a VLP, an adjuvant is needed in formulation [14, 15].  
 
Previous studies have shown that the modularization of weakly immunogenic peptide M2e from 
influenza into the molecular viral architecture provided by the polyomavirus VP1 capsomere can 
result in high immunogenicity and protection [10, 16]. These modular capsomeres can stimulate the 
immune system as they possess appropriate and immune-stimulatory molecular repetitive structure 
[5, 14] and thus may traffic into lymph nodes as was seen in a previous VLP study [17]. In addition, 
employing nano-sized particles as an adjuvant in the formulation boosted the immunogenicity of these 
modular capsomeres even though the modular capsomeres were not actively attached to the 
nanoparticles prior to injection. It was suggested that the presence of a nanoparticle in the formulation 
re-introduces the formulation particle component that is inherent in VLPs but lacking for their non-
associated subunit capsomeres [14, 15]. On the other hand, micro-sized silica adjuvant particles did 
not effectively boost the immunogenicity of modular capsomere, showing a clear and pronounced 
effect of size on the adjuvanting efficacy of the particles.  
 
While it is very interesting that a simple mixture of adjuvant nanoparticles and antigenic capsomeres 
proved highly immunogenic, understanding of the mode of action that leads to this particular immune 
response is lacking. It is unknown whether adjuvant particles and capsomere traffic separately, or 
together, after being injected into the body, even though it has already been shown that these 
components do not interact before injection [14, 15].  
 
In vivo molecular imaging has often aided in the understanding of the underlying mechanism of action 
of vaccine formulations, as elaborated in previous literature [17-20]. A variety of imaging modalities 
ranging from position emission tomography, magnetic resonance imaging through to optical 
fluorescence imaging can be employed for in vivo visualization of imaging moieties [21, 22]. Each 
of the modalities have their own advantages and disadvantages in terms of cost, complexity of 
operation, level of information and sensitivity [21, 22]. 
 
Optical fluorescence imaging is the most commonly used molecular imaging technique due to low 
cost, high versatility and relatively simple operation [23, 24]. It can be utilized to determine the 
biodistribution and clearance profile of the imaging moiety [25]. Use of excitation wavelengths in the 
near infra-red region (NIR) allows reduction of inherent tissue autofluorescence and, at the same time, 
improves the clarity and specificity of the images [26-28]. In addition to in vivo imaging, organs can 
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also be excised and analyzed ex vivo to provide semi-quantitative biodistribution information [23, 
29]. 
 
In the present study, we report on the in vivo trafficking, by fluorescent imaging, of viral modular 
capsomeres presenting M2e antigen after subcutaneous administration. We further explored the in 
vivo trafficking of this antigenic construct when formulated with silica nanoparticles and 
microparticles to better understand the observed strong dependence on size for silica adjuvant 
particles. Each of the vaccine components, i.e. modular capsomere and adjuvant particles, were 
fluorescently labeled by chemical conjugation with different near infra-red dyes, allowing them to be 
imaged at two different wavelengths in the same mouse. To the best of our knowledge, this is the first 
study that reports visualization of the movement of capsomeres in vivo after immunization. This 
optical imaging approach will help in determining whether the modular capsomere and adjuvant 
particles, when introduced in vivo, move from the injection site in unison or separately. Information 
from this study will enhance understanding of the in vivo behavior of vaccine formulations, including 
those containing particles and complex antigens, and their ability to induce an immune response.  
 
4.3. Materials and Methods 
4.3.1 Materials 
3-Aminopropyl(diethoxy)methylsilane (APDEMS), o-phenylenediamine dihydrochloride, phosphate 
citrate buffer and HRP-conjugated goat anti-mouse total IgG were purchased from Sigma-Aldrich (St 
Louis, MO) and used as supplied. Polyethylene glycol succinimidyl ester (mPEG-NSH; MW 5000) 
was purchased from Nanocs (New York, NY). PR8 M2e peptide was purchased from Peptide 2.0 Inc. 
(Chantilly, VA). IRDye® 750 NHS ester and IRDye® 650 NHS ester dye were purchased from LI-
COR Inc. (Lincoln, NE). Silica nanoparticles were purchased from Polysciences Inc. (Warrington, 
PA). Sodium chloride (NaCl), potassium chloride (KCl), disodium hydrogen phosphate (Na2HPO4), 
potassium dihydrogen phosphate (KH2PO4), Tween 20 were obtained from Chem Supply (Gillman, 
SA, Australia) of AR grade and used as supplied. 
 
4.3.2 Preparation of conjugates 
4.3.2.1 CapM2e-IRDye 650 conjugate 
Low-endotoxin CapM2e (capsomeres presenting M2e derived from influenza A/Puerto Rico/8/34 
(H1N1)) were prepared as previously described [10, 16]. Endotoxin level (<1 EU mg-1 CapM2e) was 
analyzed using LAL-based assay Endosafe PTS®-2005 (Charles River Laboratories, Wilmington, 
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MA). CapM2e concentration was adjusted to 2 mg mL-1 with endotoxin-free phosphate-buffered 
saline (PBS) and stored at -80°C until further use following thawing (4oC). IRDye 650 was added in 
excess into 2 mg mL-1 CapM2e capsomeres in a dark endotoxin-free environment and stirred at room 
temperature for 2 h. The unreacted dye was removed by using Amicon ultra centrifugal filter devices 
(nominal molecular weight cut-off of 10 kDa; Millipore, Billerica, MA, USA). CapM2e-IRDye 650 
conjugate was analyzed by size exclusion chromatography (SEC) and thin layer chromatography 
(TLC). 
 
4.3.2.2 Silica nanoparticles-IRDye 750 conjugate 
Silica nanoparticles were amine functionalized by employing 3-Aminopropyl(diethoxy)methylsilane 
(APDEMS) as described previously [15]. Polyethylene glycol succinimidyl ester (mPEG-NSH) was 
added into 2.5 mg mL-1 amine-functionalized nanoparticles (nps) in 2:1 (mPEG-NSH:Si-NH2) molar 
ratio in an endotoxin-free environment as described previously to provide colloidal stability [15]. 
IRDye 750 was then added in excess into 2 mg mL-1 pegylated silica nanoparticles in a dark 
endotoxin-free environment and stirred at room temperature for 2 h. The unreacted dye was removed 
by dialysis using snake-skin® pleated dialysis membrane (nominal molecular weight cut-off of 10 
kDa; Thermo Scientific, Rockford, IL, USA) against water at 4°C overnight and each silica 
nanoparticle-IRDye 750 conjugate (Si Np-IRDye 750 conjugate) was analyzed by dynamic light 
scattering (DLS) and TLC. 
 
4.3.2.3 Silica microparticles-IRDye 750 conjugate 
Silica nanoparticles were amine functionalized by employing 3-Aminopropyl(diethoxy)methylsilane 
(APDEMS) as described previously [15]. IRDye 750 was added in excess into 2 mg mL-1 amine 
functionalized silica nanoparticles in a dark endotoxin-free environment and stirred at room 
temperature for 2 h to obtain silica microparticles-IRDye 750 conjugate (Si Mp-IRDye 750 
conjugate). The unreacted dye was removed by dialysis using snake-skin® pleated dialysis membrane 
(nominal molecular weight cut-off of 10kDa; Thermo Scientific, Rockford, IL, USA) against water 
at 4°C overnight and the Si Mp-IRDye 750 conjugate was analyzed by DLS and TLC. 
 
4.3.3 Characterization of conjugates 
4.3.3.1 Size exclusion chromatography (SEC) 
CapM2e before and after dye conjugation were loaded into size exclusion chromatography (Superdex 
200 10/300 GL; GE Healthcare, Little Chalfont, UK) coupled with multi angle light scattering (SEC-
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MALS) pre-equilibrated in PBS with a 1100 Series Variable Wavelength Detector (Agilent 
Technologies, CA, USA) to measure UV absorbance at 280 nm and a DAWN EOS Multiple Angle 
Light Scattering detector (Wyatt Technology, CA, USA). Astra V software (version 5.3.4.18, Wyatt 
Technology, CA, USA) was used for data acquisition and analysis. Qualitative analysis of protein 
samples was performed using standard sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). 
 
4.3.3.2 Thin layer chromatography (TLC) 
To determine the extent of conjugation of dye, conjugate samples were run on a thin layer 
chromatogram (iTLC-SG; Agilent technologies, Santa clara, CA, USA) in a 1:1 ethanol: water 
mixture. Free dye was run as control. 
 
4.3.3.3 Dynamic light scattering (DLS) 
The hydrodynamic diameters of nanoparticles and microparticles in PBS solution were measured 
with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) using DLS. This instrument 
employed a 633 nm laser wavelength at a scattering angle of 173° and 4 mW He-Ne laser power. 
Nanoparticles were diluted 100-fold with PBS to avoid multiple scattering effects. Refractive index 
and viscosity of PBS were assumed to be 1.33 and 0.89 cP, respectively. 
 
4.3.4 Immunization 
Three groups of eight female 6-7 weeks old BALB/c mice (Animal Resources Centre, WA, Australia) 
were immunized with 50 g CapM2e-650 dye conjugate, alone or adjuvanted with 50 g of Si Np- 
or Si Mp-IRDye 750 conjugate. Adjuvanted CapM2e was prepared by mixing 2 mg mL-1 CapM2e-
650 dye conjugate with the selected particle-IRDye 750 conjugate in a 1:1 volume ratio shortly prior 
to injection. Three subcutaneous immunizations were given on days 0, 21 and 42. Blood samples 
were taken by tail snip before the first immunization (day 0), followed by eye bleeds on days 14 and 
35. Three mice from each group were euthanized on day 42 to collect organs for ex vivo analysis. The 
final blood sample was collected on day 56 by heart puncture. All animal experimental work was 
reviewed and approved by the University of Queensland Animal Ethics Committee (AEC approval 
number: AIBN/116/14/QSFPF). All animals were cared for humanely in accordance with the 
Australian Code for the Care and Use of Animals for Scientific Purposes. 
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4.3.5 In vivo optical imaging 
 Each mouse was shaved by using a set of small animal clippers 24 h before imaging. Prior to imaging, 
animals were anesthetised (2% isoflurane in oxygen, 1.5 L/min) and placed in an imaging cradle. 
Images were acquired at 1, 6 and 24 h post each immunization and anesthesia (2% isoflurane in 
oxygen) was maintained throughout the course of imaging via nose cone. In vivo optical imaging 
experiments were performed on an in vivo MS FX Pro instrument (now supplied by Bruker 
Corporation, Billerica, MA, USA). Fluorescence images utilizing IRDye 650 were collected with a 
630 ± 10 nm excitation and 700 nm ± 17.5 nm emission filter set (f-stop 2.80, 2 x 2 binning, 190 mm 
FOV, 30 s exposure time). Fluorescence images utilizing IRDye 750 were collected with a 730 ± 10 
nm excitation and 790 nm ± 17.5 nm emission filter set (f-stop 2.80, 2 x 2 binning, 190 mm FOV, 30 
s exposure time). To give anatomical context, fluorescence images were co-registered with an X-ray 
image (f-stop 2.80, 0.2 mm aluminum filter, 190 mm FOV, 30 s acquisition time). All images were 
batch exported as 16-bit TIFF images and image processing was completed using Image-J (National 
Institutes of Health, Stapleton, NY, USA). Fluorescence images were false colored and overlaid onto 
X-ray images. Three mice from each group were euthanized after 6 h post third immunization, and 
their organs were collected in a petri dish for ex vivo fluorescence imaging using similar settings as 
used above. 
 
4.3.6 Enzyme-linked immunosorbent assay (ELISA) 
Pierce® Streptavidin High Binding Capacity (Thermo Fisher Scientific, Waltham, MA) coated plates 
were washed 3 times with PBST (137 mM NaCl, 2.7 mM KCl, 10.15 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4, 0.05% (v/v) Tween 20). PR8 M2e peptide at 10 mg mL
-1 in PBS was adsorbed to 
the plates, 100 µL per well overnight at 4oC. Plates were washed 3 times with PBST. Plates were 
incubated with mouse sera initially at 100-fold dilution followed by four-fold serial dilutions with 
PBST containing 0.5% (w/v) skim milk (90 min, 37°C). After washing 4 times with PBST, HRP-
conjugated goat anti-mouse total IgG was added at 10, 000-fold dilution, followed by incubation (90 
min, 37°C). Plates were washed 4 times with PBST and developed (0.4 mg mL-1 o-phenylenediamine 
dihydrochloride, 50 mM phosphate citrate buffer containing 0.03% (w/v) sodium perborate) prior to 
absorbance measurement at 450 nm. End point titers were determined as the highest dilution of serum 
for which the OD was 3 standard deviations above the mean optical density of blank wells. 
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4.3.7 Statistical analysis  
Statistical analysis was performed using GraphPad Prism Version 5.03 (GraphPad Software Inc., 
USA). Comparison of more than two groups was performed with the Tukey’s multiple comparison 
tests. Comparison between two groups was performed with t test. p < 0.05 was considered statistically 
significant. 
 
4.4 Results 
This study investigated the trafficking of modular capsomere vaccine formulations in vivo in mice. 
The vaccine formulation comprised modular capsomere presenting influenza M2e antigen with or 
without formulation with silica particles at nano or micron sizes as adjuvant. Each of the vaccine 
components, i.e. CapM2e and adjuvant particles, were fluorescently labeled by chemical conjugation 
with different near infra-red dyes, allowing them to be imaged at two different wavelengths in the 
same mouse. Commercially-available activated ester optical dyes react with the primary amine groups 
present on the surface of CapM2e and silica particles to form conjugate via amide bonds. Excess dye 
was removed by either dialysis or centrifugal filtering to ensure that the fluorescent signal observed 
in vivo in mice is contributed entirely by the conjugate and not by free dye. 
 
CapM2e forms a conjugate with IRDye 650 via amide bond formation between the amine groups 
present on the surface-exposed lysine residues of CapM2e and the ester group of the dye. Stability of 
CapM2e before and after dye conjugation was analyzed by size exclusion chromatography (Figure 
4.1A). The elution time of both samples were similar indicating no significant increase in CapM2e 
size due to conjugation of dye, and that CapM2e remained stable as non-aggregated capsomere after 
conjugation. Figure 4.1B shows the SDS-PAGE gel analysis of CapM2e (lane 1), and CapM2e-IRDye 
650 conjugate before (lane 2) and after (lane 3) removal of excess dyes by coomassie blue staining 
and near infrared fluorescence imaging (Figure 4.1B). The molecular weight of CapM2e monomer 
was 40.5 kDa, as estimated by ProtParam [30], and can be seen as the prominent band in all lanes 
(Figure 4.1B). The slight smearing of this prominent band observed in lanes 2 and 3 indicates the 
small increase in CapM2e molecular weight due to conjugation with dye. Excess dye was removed 
by centrifugal filtering and its removal was further confirmed by thin layer chromatography of 
CapM2e-IRDye 650 conjugate compared to free dye (as control) which showed no remaining 
detectable free dye (Figure 4.1C). 
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Figure 4.1: Characterization of CapM2e-IRDye 650 conjugate. A) SEC chromatogram of CapM2e 
before and after dye conjugation. B) SDS-PAGE gel as visualized by coomassie blue staining (left) 
and corresponding fluorescent image (right). Lane L: Ladder, 1: CapM2e, 2: CapM2e-IRDye 650 
conjugate, 3: CapM2e-IRDye 650 conjugate (after removal of excess dye). Arrow indicates the band 
corresponding to CapM2e monomer. C) Fluorescent image of thin layer chromatogram. 1: CapM2e-
IRDye 650 conjugate, 2: free IRDye 650. 
 
Conjugation of IRDye 750 to silica particles was mediated by 3-Aminopropyl (diethoxy) 
methylsilane (APDEMS) functionalization to introduce amine functional groups on the particle 
surface. IRDye 750 was then added to amine-functionalized silica particles to generate microparticle-
IRDye 750 conjugate. To prepare Si Np-IRDye 750 conjugate, the amine-functionalized silica 
particles were stabilized by PEGylation prior to IRDye 750 conjugation. The resulting nano- and 
microparticle-IRDye 750 conjugates were characterized by DLS (Figure 4.2A), showing a particle 
diameter of 101 ± 0.7 (PdI 0.10) and 1052 ± 15 nm (PdI 0.25), respectively. Excess dye was removed 
by dialysis and its removal was confirmed by thin layer chromatography of particle-IRDye 750 
conjugates compared to free dye (as control) which showed no remaining detectable free dye (Figure 
4.2B).  
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Figure 4.2: Characterization of Si Np- and Si Mp-IRDye 750 conjugates. A) Hydrodynamic size 
distribution and B) Fluorescent image of thin layer chromatogram of (i) Si Np-IRDye 750 conjugate 
and (ii) Si Mp-IRDye 750 conjugate. Lane 1: Si Np- or Si Mp-IRDye 750 conjugate, 2: free IRDye 
750. 
 
Each vaccine formulation was administered subcutaneously into BALB/c mice. Following two 
immunizations, the level of anti-M2e specific antibody in mice was analyzed (Figure 4.3). CapM2e-
IRDye 650 conjugate without adjuvant induced an antibody endpoint titer slightly over 104, consistent 
with results observed in previous studies [10, 15]. Conjugation of dye did not significantly affect the 
immunogenicity of the unadjuvanted capsomere. The immunogenicity of CapM2e-IRDye 650 
conjugate was boosted more than 10-fold by formulating with Si Np-IRDye 750 conjugate. This 
adjuvanting effect was not observed when CapM2e-IRDye 650 conjugate was formulated with Si 
Mp-IRDye 750 conjugate. 
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Figure 4.3: M2e-specific total IgG antibody titer in BALB/c mice following two subcutaneous 
immunizations with different formulations. *, p<0.05; ns=not significant. CapM2e= CapM2e-
IRDye 650 conjugate, Np= Si Np-IRDye 750 conjugate and Mp= Si Mp-IRDye 750 conjugate. 
 
After each immunization, mice were imaged at two excitation/emission wavelengths, i.e. 630/700 
and 730/790 nm respectively, at different time points for up to 24 h. The fluorescent images were co-
registered with X-ray images to obtain anatomical information about the mice to accompany the 
optical data. The fluorescent signal corresponding to CapM2e at the injection site, i.e. near tail base, 
(Figure 4.S1) decreased with time, indicating the movement of CapM2e away from the injection site 
into general circulation. At 1 and 6 h post immunization, strong signal was observed near the bladder 
region and lymph nodes, particularly inguinal lymph nodes, which are located just above the hind 
paw, adherent to the skin of the groin (Figure 4.4A). Fluorescence signal observed in the bladder 
region suggests the subsequent clearance of CapM2e via the renal system. Most CapM2e were cleared 
from the body within 24 h post immunization, as indicated by the absence of substantial fluorescence 
thereafter or else the dye had been cleaved from CapM2e and cleared. 
 
To confirm in vivo observation, three mice from each group were euthanized after 6 hours post third 
immunization, and their organs were collected in a petri dish for ex vivo imaging (Figure 4.4B and 
4.6A). Ex vivo analysis showed similar biodistribution pattern of CapM2e as that seen during in vivo 
imaging. Strong fluorescence signal was observed in inguinal lymph nodes, followed by relatively 
lower signal in stomach and intestine region. There was negligible signal in the bladder area observed 
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during ex vivo imaging as compared to higher signal during in vivo imaging, possibly due to 
immediate excretion of CapM2e from the bladder during organ collection. 
 
 
Figure 4.4: In vivo trafficking of CapM2e (ventral view). A) Representative in vivo fluorescent 
images (co-registered to planar X-ray images) of ventral side of BALB/c mice injected with (i) 
CapM2e, (ii) CapM2e-Np, (iii) CapM2e-Mp formulation imaged at different timepoints post third 
injection corresponding to excitation wavelength of 630 nm and emission wavelength of 700 nm. B) 
Ex vivo fluorescent images (co-registered to planar X-ray images) of excised organs 6 h post third 
injection corresponding to each group. ILN: inguinal lymph nodes, S: stomach, I: intestines, SP: 
spleen, L: liver, B: bladder, K: kidneys. Magnetic strip of the imaging instrument is seen on the side 
of Petri dish. 
 
As observed during the in vivo imaging of CapM2e, the fluorescence signal corresponding to silica 
particles at the injection site also decreased with time (Figure 4.S2). Negligible signal was observed 
at 24 h post immunization, indicating that either the particles had been mostly cleared from the body 
or else the dye had been cleaved from the particle surface. At 1 and 6 h post immunization, 
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fluorescence signal for both nano- and micro-sized particles was widely spread across the 
gastrointestinal tract area, including stomach and small and large intestines, extending to the bladder 
region (Figure 4.5A). Microparticles seemed to be cleared from the body faster than nanoparticle 
counterparts as the signal correlated to microparticles was lower than that of nanoparticles at 6 h time 
point. Ex vivo analysis of mouse organs confirmed the localization of particles (Figure 4.5 and 4.6B). 
In agreement with in vivo observations, fluorescence signal was observed in the gastrointestinal tract 
area including stomach and small and large intestines. 
 
 
Figure 4.5: In vivo trafficking of adjuvant silica particles (ventral view). A) Representative in vivo 
fluorescent images (co-registered to planar X-ray images) of ventral side of BALB/c mice injected 
with (i) CapM2e, (ii) CapM2e-Np, (iii) CapM2e-Mp formulation imaged at different timepoints post 
third injection corresponding to excitation wavelength of 730 nm and emission wavelength of 790 
nm. B) Ex vivo fluorescent images (co-registered to planar X-ray images) of excised organs 6 h post 
third injection corresponding to each group. ILN: inguinal lymph nodes, S: stomach, I: intestines, 
 97 
 
SP: spleen, L: liver, B: bladder, K: kidneys. Magnetic strip of the imaging instrument is seen on the 
side of Petri dish. 
 
 
Figure 4.6: Mean fluorescence intensity (Mean ± SD; n=3) in different organs excised from 
BALB/c mice injected with CapM2e or CapM2e-Np or CapM2e-Mp formulation after 6 h post third 
injection. A) Corresponds to CapM2e collected at excitation wavelength of 630 nm and emission 
wavelength of 700 nm, B) Corresponds to adjuvant particles (Np or Mp) collected at excitation 
wavelength of 730 nm and emission wavelength of 790 nm. ILN: inguinal lymph nodes, S: stomach, 
I: intestines, SP: spleen, L: liver, B: bladder, K: kidneys. CapM2e= CapM2e-IRDye 650 conjugate, 
Np= Si Np-IRDye 750 conjugate and Mp= Si Mp- IRDye 750 conjugate. 
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4.5 Discussion 
Modular capsomere prepared using microbial cell factories is a promising rapid response and low-
cost vaccine technology [5, 31]. The capsomere is the building block of a virus-like particle (VLP), 
which is now a well-established vaccine class with the success of VLP-based human papillomavirus 
and hepatitis B virus vaccines in the market [3]. In previous studies, CapM2e has been shown to 
induce high immunogenic stimulation probably due to its appropriate and immunostimulatory 
molecular repetitive structure [5, 14], which can be further boosted by employing nano-sized silica 
adjuvant particles but not by its micro-sized counterparts [14]. The mode of action of these vaccine 
formulations is unknown. It is still to be seen firstly whether these components (capsomeres and 
adjuvant particles) move together or separately from the injection site and secondly, where they traffic 
in the body, which are studied here.  
 
It is a preliminary biodistribution study employing fluorescence imaging approach, which allowed 
imaging of two different vaccine components in the same mouse for long experiment times. These in 
vivo imaging results indicate that most of CapM2e and adjuvant particles distribute independently 
after subcutaneous immunization from the injection site. Results show that capsomeres traffic into 
inguinal lymph nodes whereas adjuvant particles traffic into the gastrointestinal tract including 
stomach and intestines. Nanoparticles and CapM2e formulated by simple mixing prior to injection 
seem to traffic separately in vivo as observed during optical imaging, yet the mere presence of nano-
sized particles in the formulation improves the overall immunogenicity. However, no such 
adjuvanting activity was seen for microparticle-based formulation, demonstrating the pronounced 
effect of size on the adjuvanticity of particles. This striking effect of size on particle adjuvanticity 
observed here is in agreement with a previous study [14], and shows that dye conjugation did not 
affect the immunogenicity of each vaccine component. These findings lead us to speculate that the 
influence of nanoparticles is on the uptake process of CapM2e at the injection site itself. The CapM2e 
and adjuvant particles seem to remain at the injection site for considerable time (up to 24 h) albeit 
with a concentration that reduces with time (Figure 4.S1 and 4.S2). A similar potent adjuvanting 
effect, despite independent trafficking of the antigen and adjuvant, has also been observed for the 
somewhat related case of soft emulsion based MF59 adjuvant [32].  
 
This size-dependent adjuvanting efficacy of silica particles is probably correlated to the higher 
clearance rate of microparticles as compared to nanoparticles since prolonged exposure of adjuvant 
particles in the body has been shown to be favorable for inducing stronger immune response [33]. 
Clearance of microparticles from the injection site within 24 h is unexpected, considering that 
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particles of such size typically remain localized as they are not able to readily enter the lymphatics or 
circulation [34]. This suggests that microparticles are being phagocytosed and actively transported to 
sites such as stomach and intestine. Nanoparticles seem to further boost the immunogenicity of 
CapM2e by introducing the particulate component which is lacking in these capsomeres. More studies 
are needed to further investigate the molecular and cellular mechanism of action of these 
formulations. 
 
The lymph node drainage of CapM2e here is as seen for VLPs in a previous study [17]. Studies have 
shown that ultra-small nanoparticles (~20nm) efficiently drain into lymph nodes [35, 36]. Since 
modular capsomeres fall into this size range, they are expected to drain directly into lymph nodes. 
Moreover, subcutaneous administration has been observed to result in the movement of particles of 
appropriate size through the lymphatic capillaries to the lymph nodes prior to reaching the general 
circulation [37, 38], which seems to occur for CapM2e in this study, following subcutaneous 
administration. 
 
The high immunogenicity of CapM2e, even in the absence of adjuvant, could be attributed to CapM2e 
trafficking to lymph nodes. Lymph nodes are a target of vaccine delivery since high concentration of 
immature dendritic cells (DCs), the most efficient antigen presenting cells, as well as cells of the 
immune system, particularly B and T cells, reside in the nodes [33, 39]. Although DCs are also present 
in peripheral tissue, they are in extremely low numbers compared to other phagocytic cells such as 
macrophages [33] and therefore, compete unfavorably in antigen uptake, resulting in ineffective DC-
dependent immune response activation. In addition, capsomeres possess pathogen-associated 
molecular patterns (PAMPs), that can act as a danger signal to the immune system and can in turn 
activate the pattern recognition receptors on cells of the innate immune system [40]. 
 
This study, to the best of our knowledge, is the first report on capsomere trafficking in vivo in mice 
and will contribute to the development of modular capsomere vaccine technologies. It has provided 
insight into the in vivo behavior of these vaccine formulations and their capacity to induce antibody-
biased immune responses. Moreover, the clearance pattern of the nanoparticle-based formulation 
observed during this study was encouraging and contributes to the safety characteristic of the vaccine. 
In other studies, modular capsomeres comprising influenza M2e antigen have been demonstrated to 
protect mice during viral challenge as evidenced by reduced disease severity and reduced viral load 
in the lungs [16]. Molecular imaging is useful because it allows for non-invasive repeat measurements 
of the in vivo fate of the imaging moieties rather than usually employed standard end-point analyses. 
Radioisotopic imaging such as positron emission tomography (PET) can be carried out in future to 
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confirm these observations and further elucidate quantitative information about the biodistribution 
and clearance mechanism of the vaccine formulations. 
 
To summarize, an optical imaging approach was used to directly observe the trafficking of vaccine 
components after subcutaneous immunization and the corresponding humoral immune response was 
also analyzed in this study. We conclude that modular capsomeres mostly traffic into lymph nodes 
upon immunization and get cleared from the body within 24 h post immunization via renal clearance. 
Both the adjuvant particles i.e. nano-and micron-sized silica particles accumulate in the 
gastrointestinal tract, particularly the intestinal region, though microparticles appear to be cleared 
from the body at a faster rate than their nanoparticle counterparts. This study confirmed that silica 
nanoparticles boosts the immunogenicity of CapM2e, even though CapM2e and nanoparticles traffic 
independently in vivo. 
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4.10 Supplementary material 
 
 
Figure 4.S1: In vivo trafficking of CapM2e (dorsal view). Representative in vivo fluorescent images 
(co-registered to planar X-ray images) of dorsal side of BALB/c mice injected with (i) CapM2e, (ii) 
CapM2e-Np, (iii) CapM2e-Mp formulation imaged at different timepoints post third injection 
corresponding to excitation wavelength of 630 nm and emission wavelength of 700 nm. 
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Figure 4.S2: In vivo trafficking of adjuvant silica particles (dorsal view). Representative in vivo 
fluorescent images (co-registered to planar X-ray images) of dorsal side of BALB/c mice injected 
with (i) CapM2e, (ii) CapM2e-Np, (iii) CapM2e-Mp formulation imaged at different timepoints post 
third injection corresponding to excitation wavelength of 730 nm and emission wavelength of 790 
nm. 
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Chapter 5 
 
Modular virus-like particles for sublingual vaccination against group A 
streptococcus 
 
The entire Chapter 5 consists of the peer-reviewed journal article published as: 
 
Seth A†, Kong IG†, Lee S-H, Yang J-Y, Lee Y-S, Kim Y, Wibowo N, Middelberg APJ, Lua LHL, 
Kweon M-N* (2016). Modular virus-like particles for sublingual vaccination against group A 
streptococcus. Vaccine 34(51), 6472-6480. 
†These authors contributed equally. 
 
The following modifications were made to the article:  
− Page numbers of the original article were changed into the numbers consistent with those on 
the remainder of the thesis page numbers.  
− Figure numbers were changed into the numbers consistent with the remainder of figures in 
the thesis.  
− Section and sub-section numbers were changed into the numbers consistent with the 
remainder of sections and sub-sections in all chapters of the thesis.  
− The reference style of the original article was changed into the style consistently used in all 
chapters of the thesis. 
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5.1 Abstract 
Infection with Group A streptococcus (GAS)—an oropharyngeal pathogen—leads to mortality and 
morbidity, primarily among developing countries and indigenous populations in developed 
countries. The development of safe and affordable GAS vaccines is challenging, due to the presence 
of various unique GAS serotypes, antigenic variation within the same serotype, and potential auto-
immune responses. In the present study, we evaluated the use of a sublingual freeze-dried (FD) 
formulation based on immunogenic modular virus-like particles (VLPs) carrying the J8 peptide (J8-
VLPs) as a potential safe and cost-effective GAS vaccine for inducing protective systemic and 
mucosal immunity. By using in vivo tracing of the sublingual J8-VLPs, we visualized the draining 
of J8-VLPs into the submandibular lymph nodes, in parallel with its rapid absorption into the 
systemic circulation, which support the induction of effective immune responses in both systemic 
and mucosal compartments. The sublingual administration of J8-VLPs resulted in a high serum IgG 
antibody level, with a good balance of Th1 and Th2 immune responses. Of note, sublingual 
vaccination with J8-VLPs elicited high levels of IgA antibody in the saliva. The co-administration 
of mucosal adjuvant cholera toxin (CT) further enhanced the increase in salivary IgA antibody 
levels induced by the J8-VLP formulation. Moreover, the levels of salivary IgA and serum IgG 
observed following the administration of the CT-adjuvanted FD formulation of J8-VLPs (FD-J8-
VLPs) and non-FD formulation of J8-VLPs were comparable. In fact, the saliva isolated from mice 
immunized with J8-VLPs and FD-J8-VLPs with CT demonstrated opsonizing activity against GAS 
in vitro. Thus, we observed that the sublingually-delivered FD formulation of microbially produced 
modular VLPs has potential to cost-effectively prevent and control GAS diseases in areas where 
they are endemic. 
 
5.2 Introduction 
Group A streptococcus (GAS) is a major pathogen that causes pharyngitis and pyoderma, or even 
serious invasive diseases such as rheumatic fever and pyelonephritis [1, 2]. The development of 
affordable and safe GAS vaccines is an essential and effective approach to prevent GAS infection 
worldwide. The candidate antigens for GAS vaccine development should be safe—i.e., should not 
provoke an autoimmune response to human tissue—and should be highly conserved among various 
GAS serotypes. Moreover, the production of appropriate levels of protective antibody is essential [3, 
4]. Of the several antigen candidates investigated so far [3, 5], p145—an -helical peptide from the 
conserved C-repeat domain of GAS M protein—is a well-documented antigen that is not auto-
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immunogenic. J8i is a minimal B cell epitope (12 amino acid sequence) of p145 that is designed to 
minimize the possibility of cross-reactivity to human antigens [4, 6]. In fact, J8i is the main peptide, 
and is flanked by a GCN4 linker to maintain the helical conformation; the entire sequence is simply 
referred to as J8 [4, 6, 7]. J8 has been reported to generate opsonizing antibodies against multiple 
GAS strains [8, 9]. Different vaccine delivery systems for the J8i antigen, such as lipid core peptide 
system and virus-like particles (VLPs), have been explored to potentiate its immunogenicity [5, 10]. 
 
VLPs—highly ordered assemblies of viral capsid proteins—are now a well-developed class of 
vaccine [11-13], supported by the commercial success of different VLP-based vaccines [14-16]. 
Modularized VLPs are also being employed as delivery platforms for vaccines against diseases 
other than those caused by the parent VLPs, through the presentation of the appropriate target 
antigen on the surface [10, 17, 18]. Moreover, VLPs are highly immuno-stimulatory and self-
adjuvanting, probably due to their highly ordered repetitive structure and particle characteristics [11, 
19, 20]. Previous studies have demonstrated the effectiveness of modular murine polyomavirus VP1 
VLPs presenting J8 antigen (J8-VLPs) in inducing systemic opsonization antibodies upon 
subcutaneous immunization and conferred protection against lethal challenge upon intranasal 
delivery in a follow-up [10, 21]. 
 
Delivery through the sublingual mucosa induces both mucosal and systemic immunity, and 
represents the most suitable strategy against oropharyngeal GAS pathogens. Sublingual delivery 
offers several other advantages such as better patient compliance, rapid onset of action, non-
invasive nature and high bioavailability, and ease of self-medication [22, 23]. The effectiveness of 
sublingual vaccination of VLPs has been demonstrated previously. Sublingually-administered 
human papillomavirus VLPs were shown to confer protection against genital challenge [24]. 
Moreover, the freeze drying process improves the shelf life of proteins and allows cold-chain free 
transportation and storage [25, 26]. The potential of the sublingual wafer freeze dried (FD) 
formulation is supported by the regular use and availability of such formulations of drugs (Zydis® 
Bio) that have been approved for human use; and some of them are in clinical or pre-clinical studies 
[27, 28]. In our current study, we explored the potential of sublingually-administered FD-J8-VLPs 
as a cost-effective potent GAS vaccine that can be delivered to remote communities in developing 
countries where GAS diseases are endemic. 
 
Sublingually administered J8-VLPs induced high levels of systemic IgG and mucosal IgA 
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antibodies. The movement of J8-VLPs in mice after immunization via sublingual and subcutaneous 
routes was tracked by using fluorescence optical imaging, which showed differences in the 
biodistribution, particularly in terms of lymph node involvement. Furthermore, the administration 
of FD-J8-VLPs with the mucosal adjuvant cholera toxin (CT) induced a considerable systemic and 
mucosal antibody response, comparable with that induced by its J8-VLP counterpart with CT. By 
demonstrating that the salivary IgA antibodies showed in vitro bactericidal activity against GAS, 
this study indicates the potential of sublingually-administered FD-J8-VLP that can block horizontal 
transmission by eradicating the pharyngeal colonization of GAS. 
 
5.3 Materials and methods 
5.3.1 Protein expression and purification 
WT-VP1 and J8-VP1 were expressed as GST-tagged capsomeres and purified as previously 
described [10, 21]. The endotoxin was removed from the purified capsomeres by using an anion 
exchanger, Vivapure Q Mini M spin column (Sartorius Stedim, France) and tested, as previously 
described [10].  
 
5.3.2 Assembly, concentration and analysis of VLPs 
Low-endotoxin capsomeres, J8-Cap and WT-Cap, were assembled into J8-VLPs and WT-VLPs via 
dialysis, as described previously [10, 29]. The VLPs were analyzed using transmission electron 
microscopy (TEM) as well as asymmetric flow field-flow fractionation (AF4) coupled with multi-
angle light scattering (MALS), as described previously [29, 30], and stored at -80°C until further 
use. 
 
5.3.3 Freeze drying of VLPs 
J8-VLPs, stabilized by 40% w/v sorbitol and 0.5% w/v polysorbate 20, were FD as described 
previously [31]. FD-J8-VLPs were analyzed using TEM and AF4-MALS after rehydration with 
deionized water and incubation on a roller mixer at 25°C for 30 min. 
 
5.3.4 Preparation of J8-VLP-IRDye 650 conjugate 
IRDye 650 was added in excess into the 2.5 mg mL-1 samples of J8-VLPs in a dark endotoxin-free 
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environment and stirred at room temperature for 2 h. The unreacted dye was removed by using 
Amicon ultra centrifugal filter devices (nominal molecular weight cut-off, 10 kDa; Millipore, 
Billerica, MA), and the J8-VLP-IRDye 650 conjugate was analyzed via dynamic light scattering 
(DLS) and thin layer chromatography (TLC). 
 
5.3.5 Immunization of mice  
Female BALB/c mice (6–7-weeks-old) were immunized with the vaccine candidates 
subcutaneously or sublingually at day 0, 7, and 21. The amount of immunized antigen was as 
follows: J8-VLPs (50 µg) with or without cholera toxin (CT; 1 µg; List Biological Laboratory, 
Campbell, CA); FD-J8-VLPs (50 µg) with or without CT (1 µg); or WT-VLPs in 25 μL volume per 
mouse. All experiments were performed in accordance with the Guidelines for Use and Care of 
Experimental Animals, and had been approved by the institutional review board of Asan Medical 
Center (IACUC approval number: 2014-12-061). Two weeks after the second and third 
immunization, sera and saliva were collected from each mouse. For the imaging study, a similar 
immunization regime was followed. Two groups of 8 female BALB/c mice (Animal Resources 
Centre, WA, Australia) were immunized subcutaneously or sublingually with 50 μg of J8-VLPs. All 
the animal experimental work was reviewed and approved by the University of Queensland Animal 
Ethics Committee (AEC approval number: AIBN/285/15). All animals were cared for humanely in 
accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes. 
 
 
5.3.6 In vivo optical imaging 
Each mouse was shaved by using small animal clippers 24 h before imaging. After anesthetizing the 
mice (2% isoflurane in oxygen, 1.5 L min-1), images were acquired at 1, 4, 8, 12, 24, and 48 h after 
each immunization by using an in vivo MS FX Pro instrument (Bruker Corporation, Billerica, MA). 
Fluorescence images utilizing IRDye 650 were acquired with a 630 ± 10 nm excitation and 700 nm 
± 17.5 nm emission filter set (f-stop, 2.80; 2 × 2 binning; field of view, 120 mm; exposure time, 10 
s). To give anatomical context, fluorescence images were co-registered with an X-ray image (f-stop, 
2.80; 0.2 mm aluminum filter; field of view, 120 mm; acquisition time, 120 mm). All images were 
batch-exported as TIFF images and image processing was conducted using Image-J (National 
Institutes of Health, Stapleton, NY). Fluorescence images were false-colored and overlaid onto the 
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X-ray images. Three mice from each group were euthanized 4 h after the third immunization, and 
their organs were collected in a petri dish for ex vivo fluorescence imaging under similar settings as 
those mentioned above. 
 
5.3.7 Determination of antibody titers 
J8i-specific antibody levels were analyzed via ELISA according to a previously reported procedure 
with some modifications [10, 13]. Biotinylated J8i peptide (10 μg mL-1) in PBS was absorbed to the 
plate (Pierce Streptavidin High Binding Capacity-coated plate (Thermo Fisher Scientific, Waltham, 
MA)) for 2 h at room temperature. After washing, serum or saliva samples with adequate dilution in 
1% BSA-PBS were loaded on the plate and incubated for 90 min at 37°C. HRP-conjugated goat 
anti-mouse IgG, IgG1, IgG2a, IgG2b, or IgA antibodies (Southern Biotech, Birmingham, AL) were 
used at 3000-fold dilution, and the reactions were visualized with the TMB Microwell Peroxidase 
Substrate System (XPL, Gaithersburg, MD). The end-point titers were expressed as the reciprocal 
log 2 of the last dilution that provided an OD450 that was >0.1 unit greater than that of the negative 
control. 
 
5.3.8 Bactericidal assay 
Bactericidal assay was performed according to a previously published protocol [8-10, 32]. In brief, 
50 μL of pooled saliva of each group of immunized mice was collected and heat-inactivated at 60°C 
for 10 min. Samples with GAS dilution at the stationary phase were mixed and incubated at room 
temperature for 20 min. Pre-tested non-opsonic heparinized human blood was added and incubated 
at 37°C for 3 h, and the mixture was plated on a THB agar plate. After overnight incubation at 37°C, 
the number of bacterial colonies was counted and the percent reduction in colony-forming units 
(CFU) was calculated through a comparison of the mean CFU of the control group, the WT-VLP-
immunized group. The Streptococcus pyogenes strains utilized in this study have been described 
previously [33]. 
 
5.3.9 Statistical analysis 
Data are expressed as means ± standard deviation. Statistical significance was analyzed with 
Tukey’s t-test. Data were considered as statistically significant when the p value was <0.05.  
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5.4 Results 
5.4.1 Analysis of in vitro-assembled VLPs 
WT-VLPs and J8-VLPs were prepared as described previously [10]. Both the VLPs were 
characterized using AF4-MALS (Figure 5.1A and 5.1B) and TEM analyses (Figure 5.1D and 5.1E) 
which showed that the VLPs were monodisperse and did not contain aggregates. The J8-VLPs were 
then FD as described previously [31] and the FD formulation was also characterized using AF4-
MALS (Figure 5.1C) and TEM (Figure 5.1F). The main peaks corresponding to WT-VLPs, J8-
VLPs, and FD-J8-VLPs were eluted at 16–20 min on AF4 fractograms. For FD-J8-VLPs, an 
additional peak corresponding to polysorbate 20 was eluted at 10–13 min on the fractogram (Figure 
5.1C). Furthermore, no aggregate peak was observed at 40–45 min on the fractogram of FD-J8-
VLPs, which indicated that the J8-VLPs were stable after FD. 
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Figure 5.1: Analysis of in vitro assembled virus-like particles. Asymmetrical flow field-flow 
fractogram of (A) WT-VLPs; (B) J8-VLPs; and (C) FD-J8-VLPs. Transmission electron micrograph 
of (D) WT-VLPs; (E) J8-VLPs; and (F) FD-J8-VLPs. Scale bars represent 200 nm. 
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5.4.2 In vivo trafficking of J8-VLPs 
For in vivo imaging, the J8-VLPs were fluorescently labeled by chemical conjugation with a near-
infrared dye, IRDye 650. The stability of the J8-VLPs before and after conjugation was analyzed 
via DLS (Figure 5.2A). The hydrodynamic size distribution of both samples was similar, indicating 
that there was no significant increase in J8-VLP size after conjugation with the dye, and the 
conjugated J8-VLPs remained stable. TEM image of the J8-VLP-IRDye 650 conjugate (Figure 5.2B) 
showed that the conjugate had similar morphology to J8-VLPs (Figure 5.1B). Excess unreacted dye 
was removed by centrifugal filtering and confirmed by TLC comparison of J8-VLPs-IRDye 650 
conjugate and free dye. As expected, no remaining measurable free dye was detected by TLC in the 
conjugated VLP sample (Figure 5.S1). 
 
The in vivo trafficking of J8-VLPs administered subcutaneously and sublingually was visualized by 
NIR fluorescence imaging. The subcutaneously-administered labeled J8-VLPs were detected at the 
injection site, i.e., the tail base (Figure 5.2C), as shown on dorsal views. The fluorescent signal at 
the injection site decreased over time and was significantly reduced after 24 h. In case of sublingual 
immunization, the antigen remained at the administration site, i.e., the sublingual mucosa, for up to 
12 h, and reduced over time (Figure 5.2D). The subcutaneously-administered J8-VLPs produced a 
strong fluorescent signal in the lower portion of the ventral side in mice, suspected to be the bladder, 
from 4 to 24 h after immunization (Figure 5.2C). For the sublingually-administered J8-VLPs, 
fluorescence was detected in the liver at 1, 4, and 8 h after immunization (Figure 5.2D, dorsal view) 
and in the gastrointestinal tract at 1 and 4 h after immunization (ventral view).  
 
To confirm the in vivo findings, 3 mice from each group were euthanized 4 h after the third 
immunization, and their organs and lymph nodes were extracted for ex vivo analysis. The ex vivo 
imaging study showed strong detectable fluorescence in the lumbar and sciatic lymph nodes, 
followed by a relatively lower signal in the bladder, stomach, and intestine region, in the case of 
subcutaneous administration (Figure 5.2E). In contrast, for the sublingually-administered J8-VLPs, 
strong fluorescence was observed in the submandibular lymph node, liver, stomach, colon, and 
caecum region of the intestine and sublingual mucosa (Figure 5.2F).  
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Figure 5.2: In vivo trafficking of J8-VLPs. Hydrodynamic size distribution of J8-VLPs before and 
after conjugation (A) and transmission electron micrograph of the J8-VLP-IRDye 650 conjugate (B). 
Representative in vivo fluorescent images (co-registered with planar X-ray images) of the dorsal (d) 
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and ventral (v) sides of BALB/c mice administered subcutaneously (C) and sublingually (D) with 
J8-VLPs, imaged at different time points after injection, corresponding with an excitation 
wavelength of 630 nm and emission wavelength of 700 nm. (E, F) Ex vivo fluorescent images (co-
registered with planar X-ray images) of excised organs 4 h after injection, corresponding to each 
group. ILN: inguinal lymph nodes, SCLN: sciatic lymph nodes, PLN: popliteal lymph nodes, SALN: 
sacral lymph nodes, LLN: lumbar lymph nodes, MLN: mesenteric lymph nodes, CLN: cervical 
lymph nodes, BLN: brachial lymph nodes, TH: thymus, SMLN: submandibular lymph nodes, T: 
tongue, B: bladder with ureter, L: liver with gall bladder, LU: lung, H: heart, P: pancreas, S: 
stomach, SI: small intestine, SP: spleen, K: kidneys, CA: caecum, CO: colon. 
 
5.4.3 Sublingual vaccination with J8-VLPs elicited both systemic and mucosal antibodies 
To investigate the efficacy of the VLP vaccine candidates, groups of mice were sublingually 
immunized three times with either WT-VLPs or J8-VLPs. As expected, sublingual immunization 
with WT-VLPs did not induce any J8i antigen-specific antibodies in both the serum and saliva 
(Figure 5.3A). Mice vaccinated sublingually with J8-VLPs exhibited predominant levels of IgG 
antibody in the serum after the second and third immunizations (Figure 5.3A). Similarly, the levels 
of IgA antibody in the saliva were also significantly higher in mice administered J8-VLPs via the 
sublingual route as compared to those in the WT-VLP group (Figure 5.3A). Although subcutaneous 
vaccination with J8-VLPs elicited high levels of serum IgG antibody, no IgA antibody was detected 
in the saliva (Figure 5.3A). These data demonstrate that sublingually-administered J8-VLP is highly 
immunogenic and induces both systemic and mucosal immune responses.  
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Figure 5.3: Systemic IgG and mucosal IgA antibodies elicited by sublingual vaccination with J8-
VLPs. BALB/c mice were sublingually vaccinated on days 0, 7, and 21 with WT-VLPs or J8-VLPs. 
At 2 weeks after the second and third immunization, serum and saliva samples were collected and 
analyzed for J8i antigen-specific antibody using ELISA. (A) The levels of J8i antigen-specific IgG 
antibody in the serum and IgA antibody in the saliva were determined. In another experimental set, 
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BALB/c mice were vaccinated on days 0, 7, and 21 sublingually with WT-VLPs or J8-VLPs 
with/without CT or subcutaneously with J8-VLPs. The levels of J8i antigen-specific IgG antibody in 
the serum and IgA antibody in the saliva (B), as well as the IgG subclasses in serum (C) were 
assessed using ELISA. Data are presented as mean ± standard deviation for 5 mice per group. 
Experiments were repeated at least 3 times. **p < 0.01, ***p < 0.001 versus WT-VLP-SL group by 
Tukey’s t-test. 
 
To address whether the addition of adjuvants can enhance the immunogenicity of J8-VLPs, we used 
the well-known mucosal adjuvant CT. Groups of mice were immunized sublingually with J8-VLPs 
in the presence or absence of CT. Two weeks after the second and third sublingual immunizations, 
the levels of IgG antibody in the serum were higher in the J8-VLP+CT mice than in the J8-VLP 
mice (Figure 5.3B). Most importantly, sublingual vaccination with J8-VLP+CT resulted in 
significantly higher levels of IgA antibody in the saliva, compared to those in the J8-VLP group 
(Figure 5.3B). Subclass analysis of the serum IgG revealed IgG1 (Th2-type) dominance, followed 
by identical levels of IgG2a (Th1-type) and IgG2b (Th1+Th2-type), for groups immunized with J8-
VLPs or J8-VLPs+CT administered sublingually (Figure 5.3C). Sublingual vaccination with J8-
VLP+CT elicited a higher level of IgG1, IgG2a and IgG2b, as compared to that with J8-VLPs. Thus, 
sublingual vaccination with the J8-VLP formulation resulted in increase in the levels of both 
systemic IgG and mucosal IgA antibodies, along with well-balanced Th1 and Th2-type responses; 
however, a mucosal adjuvant might be essential for enhancing the production of mucosal IgA 
antibodies. 
 
5.4.4 Efficacy of sublingually-delivered FD-J8-VLPs 
To test the viability of the cold-chain free formulation of J8-VLPs, we attempted to manufacture a 
FD formulation and evaluate its in vivo immunogenicity. Groups of mice were immunized 
sublingually with FD-J8-VLPs in the presence or absence of CT. Identical high levels of IgG 
antibody were found in the serum of mice that were sublingually vaccinated with FD-J8-VLPs after 
the second and third immunizations (Figure 5.4), in comparison with those sublingually vaccinated 
with J8-VLPs (Figure 5.3A). The addition of CT in the formulation improved the serum IgG levels 
elicited by FD-J8-VLP administration (Figure 5.4). Unexpectedly, FD-J8-VLPs elicited a lower 
level of IgA antibody in the saliva even after the second and third immunization (Figure 5.4), 
compared to that elicited by J8-VLPs (Figure 5.3B). However, the co-administration of CT 
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significantly boosted the salivary IgA antibody response induced by the sublingually-administered 
FD-J8-VLPs (Figure 5.4). 
 
Figure 5.4: Efficacy of sublingual vaccination with freeze-dried (FD) J8-VLPs. The levels of J8i 
antigen-specific IgG antibody in the serum and IgA antibody in the saliva were determined 
following vaccination with the FD formulation. Data are presented as mean ± standard deviation 
for 5 mice per group. Experiments were repeated at least 3 times. **p < 0.01, ***p < 0.001 versus 
WT-VLP-SL group by Tukey’s t-test. 
 
5.4.5 Protective efficacy of mucosal antibodies elicited by sublingual vaccination with J8-VLPs 
Since there is no available in vivo assay to measure the bactericidal activity of GAS, we instead 
adopted an in vitro assay using the saliva collected from mice after immunization with various J8-
VLP formulations. As expected, no bactericidal activity against GAS was found in the saliva 
obtained from mice immunized sublingually with WT-VLPs or subcutaneously with J8-VLPs 
(Figure 5.5). Importantly, higher levels of bactericidal activity were found in the saliva obtained 
from mice vaccinated with J8-VLPs sublingually as compared to those in mice vaccinated 
sublingually with WT-VLPs or subcutaneously with J8-VLPs (Figure 5.5). Although we currently 
cannot explain why sublingual vaccination with FD-J8-VLPs elicited lower levels of IgA antibody 
(Figure 5.4) and bactericidal activity (Figure 5.5), these limitations can be overcome by adding 
mucosal adjuvants such as CT. Overall, sublingual vaccination with J8-VLPs or FD-J8-VLP+CT 
yielded significant advantages for building protective efficacy against GAS infection. 
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Figure 5.5: Bactericidal activity against GAS in vitro. Saliva samples were collected from the mice 
immunized sublingually with J8-VLPs, FD-J8-VLPs with/without CT, or WT-VLPs (control), or 
subcutaneously with J8-VLPs. Data are presented as mean ± standard deviation for 5 mice per 
group. Experiments were repeated at least 3 times. **p < 0.01, ***p < 0.001 versus WT-VLP-SL 
group by Tukey’s t-test. 
 
5.5 Discussion and Conclusions 
In the present study, sublingually-administered J8-VLPs elicited higher levels of salivary IgA and 
serum IgG antibodies even after the second immunization. The systemic and mucosal immune 
responses induced by sublingually-administered J8-VLPs appeared to peak after only 2 
immunizations, and were comparable with those induced by J8-VLP administration after 3 
immunizations in previous studies [10, 21, 34]; this emphasizes the immunological advantage of 
sublingual delivery over traditional delivery.  
 
The serum level of IgG antibody induced by J8-VLPs was comparable in groups of mice vaccinated 
through the subcutaneous or sublingual routes (Figure 5.3A). However, importantly, the sublingual 
administration of J8-VLPs resulted in a significantly higher IgA antibody response in the saliva, in 
comparison with subcutaneous administration (Figure 5.3A), which is important for providing 
protection at the mucosal site. Furthermore, the co-administration of CT adjuvant with J8-VLPs 
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resulted in a significant boost in the IgA antibody level following sublingual immunization, 
although there were only small increments in the serum IgG antibody level (Figure 5.3B). In 
addition, balanced Th1 and Th2 responses were observed for sublingually-administered J8-VLPs in 
the presence or absence of CT (Figure 5.3C). Previous studies have indicated that murine IgG2a and 
IgG2b subclasses are associated with opsonizing activity, which might be beneficial for bacterial 
clearance [9, 35]. These results show that the administration of J8-VLPs alone is sufficiently 
immunogenic to induce an immune response in both the mucosal and systemic compartments, along 
with balanced Th1 and Th2 responses. 
 
To our knowledge, this is the first report to analyze the trafficking of sublingually-administered 
VLPs in vivo. The subcutaneously-administered VLPs are localized in the sciatic and lumbar lymph 
nodes, whereas the sublingually-administered VLPs were observed in the submandibular lymph 
nodes (Figure 5.2). The draining of the antigen into the submandibular lymph nodes is supported by 
previous reports, wherein antibody-secreting cells were observed in the submandibular lymph nodes 
upon sublingual administration of antigens [36, 37]. The high immunogenicity of these VLPs 
administered sublingually or subcutaneously could be attributed to their trafficking into lymph 
nodes. Higher lymph node involvement is correlated with stronger immune response, as it implies 
that a greater number of antigens have reached the lymph nodes. Moreover, these lymph nodes have 
a high concentration of immune cells, particularly dendritic cells and B and T cells [38, 39].  
 
The signal in the lymph nodes, including the lumbar, sciatic, and submandibular lymph nodes, 
could only be observed during ex vivo analysis. This could be attributed to either their interior 
location or closeness to the immunization site, which would prevent the detection of fluorescence in 
these nodes during in vivo imaging. For subcutaneous immunization, a lower signal in the bladder 
area was observed during ex vivo imaging, compared to the higher signal observed during in vivo 
imaging, possibly due to its immediate excretion from the bladder. The J8i antigen-specific 
antibody titers obtained following conjugated J8-VLP administration were consistent with those 
observed following non-labeled J8-VLP administration, indicating that conjugation with dye did not 
significantly affect the immunogenicity of the VLPs (Figure 5.S2). 
 
The effect of freeze drying on the established high immunogenicity of sublingually-delivered J8-
VLPs was investigated in vivo. We found that freeze drying did not affect its ability to induce a 
systemic immune response, although it did affect the mucosal immune response (Figure 5.4). This 
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decrease in the IgA antibody level in the saliva could either be due to the lower sublingual delivery 
efficiency of these FD-J8-VLPs or due to the reduced activity of FD-J8-VLPs as a result of 
aggregation. However, by adjuvanting the FD formulation with CT, the induced salivary IgA levels 
were boosted to the level induced by the CT-adjuvanted non-FD J8-VLP formulation (Figure 5.4). 
Nevertheless, to improve the mucosal response without the use of mucosal adjuvant, further 
research is required, and up-dosing or reprocessing to express more epitopes can be considered, 
along with the further optimization of the FD formulation.  
 
Mucosal IgA antibodies were detected in the saliva samples obtained from groups immunized 
sublingually with different J8-VLP formulations in the presence or absence of CT (Figure 5.3B and 
5.4). The protective immunity against GAS is considered to be antibody-mediated. In fact, studies 
in mice have shown that mucosal IgA in the saliva, induced by intranasal vaccination against GAS, 
prevents the colonization and adherence of GAS to the mucosal site after an intranasal challenge 
[40-42]. Therefore, the induction of salivary IgA responses after mucosal immunization is an 
important aspect of protective GAS vaccine development. 
 
Sublingual administration with J8-VLPs and CT adjuvanted FD-J8-VLP formulations, which 
elicited high levels of saliva IgA antibody, showed strong opsonizing capacity (Figure 5.5). These 
data show that sublingual immunization with J8-VLPs induced effective mucosal immunity that 
could block the colonization of GAS at the pharyngeal mucosa.  
 
There are more than 100 identified GAS serotypes [43, 44], which makes it difficult to develop an 
effective vaccine that can provide sufficient coverage against distinct circulating strains in a GAS-
affected region. VLPs can serve as a multivalent vaccine, as they can incorporate multiple-strain-
specific antigenic determinants and thus provide expanded coverage against multiple GAS strains. 
Such a multivalent approach has already been effective for human papillomavirus VLP-based 
vaccines against cervical cancer [16].  
 
To our knowledge, this is the first report to evaluate the effectiveness of sublingually-administered 
modular VLP-based GAS vaccines. These FD microbially produced VLPs can facilitate cost-
effective and protective mucosal vaccine delivery in poor remote communities that are most 
severely affected by GAS diseases, without the need for highly trained personnel. Further work to 
improve their efficacy will require the optimization of FD formulation in terms of dose and stability. 
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5.9 Supplementary material 
 
Figure 5.S1: Fluorescent image of thin layer chromatogram of J8-VLP-IRDye 650 conjugate 
and free IRDye 650. 
 
 
Figure 5.S2: Systemic IgG and mucosal IgA antibodies elicited by subcutaneous and sublingual 
vaccination with J8-VLP-IRDye 650 conjugate. The levels of antigen-specific IgG antibody in the 
serum and IgA antibody in the saliva were determined. Data are presented as mean ± standard 
deviation for 5 mice per group. **p < 0.01, ***p < 0.001, Tukey’s t-test.  
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Chapter 6 
 
Conclusions and future work 
 
6.1 Summary of key research findings 
Vaccine development is moving towards subunit compositions in this modern era, which are safer 
and easier to produce than traditional live or inactivated vaccines. However, subunit vaccines can be 
less immunogenic [1]. This necessitates new approaches to boost the immunogenicity of new 
generation of subunit vaccines. One approach utilizes delivery systems for antigens such as virus-
like particles (VLPs) that harness the immunostimulating properties of pathogens namely; highly 
ordered repetitive structure, particulate size, molecular pattern and ability to generate innate 
immunity. 
 
A robust and versatile microbial platform that utilizes the murine polyomavirus (MPyV) capsid 
protein VP1 to display antigenic modules from pathogens had been reported [2]. The flexibility of 
this platform has been shown with modular VLPs and capsomeres against GAS and influenza, 
respectively [2-4]. These microbially-produced candidates are cheap, stable, and amenable to mass 
production [5, 6]. This thesis enhanced the efficacy of these vaccine candidates by employing 
adjuvants and alternative routes of administration. Moreover, an increased understanding of where 
these formulation traffic in vivo and how that affects the immune response will allow the rational 
designing of potent vaccine formulations. The approach used to bridge this knowledge gap was in 
vivo fluorescence optical imaging, which visualized the in vivo trafficking of the vaccine 
formulations. 
 
The experimental work discussed in this thesis was designed to explore three key aspects in 
improving the efficacy of vaccine candidates based on VLPs and capsomeres, targeting influenza A 
and GAS: 
I. Non-carrier nanoparticles as adjuvant for modular capsomeres (Chapter 3) – This study 
revealed that non-carrier silica and PLGA nanoparticles significantly enhance the 
immunogenicity of modular capsomere presenting influenza M2e antigen (CapM2e), with 
an antibody-biased immune response. No significant effect on the adjuvanticity of silica 
nanoparticles was observed on varying their surface charge. 
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II. In vivo trafficking of mixed silica nanoparticle and modular capsomere vaccine formulation 
(Chapter 4) – In vivo fluorescence imaging study showed that modular capsomere drain into 
inguinal lymph nodes, which could be responsible for their high immunogenicity, even in 
the absence of adjuvant. On the other hand, adjuvant particles i.e. nano-and micron-sized 
silica particles traffic independently into gastrointestinal tract, with microparticles clearing 
faster than their nanoparticle counterparts. This study corroborated the adjuvanting effect of 
silica nanoparticles on modular capsomeres, even though these components traffic 
separately in vivo. 
III. Efficacy of sublingually-administered modular VLPs and their in vivo trafficking (Chapter 
5) – Sublingual delivery of modular VLPs presenting GAS J8 antigen (J8-VLPs) induced 
high levels of salivary IgA and serum IgG with well-balanced Th1 and Th2 immune 
responses. This was supported by observed trafficking of VLPs into submandibular lymph 
nodes with concurrent rapid absorption into systemic circulation, visualized by in vivo 
fluorescence imaging. Mucosal adjuvant cholera toxin (CT) boosted the salivary IgA level 
generated by J8-VLPs. Co-administration of CT with freeze-dried formulation of J8-VLPs 
resulted in induction of high level of IgA and IgG antibodies, which was similar to the level 
induced by CT-adjuvanted non-freeze-dried J8-VLP counterparts. In vitro bactericidal assay 
showed the ability of sublingually-administered J8-VLPs to generate opsonizing antibodies 
against GAS. 
 
The following sections describe these key research findings of this project obtained from the 
experimental work in more detail: 
 
6.1.1 Non-carrier nanoparticles as adjuvant for modular capsomeres  
This study investigated the adjuvanting efficacy of similarly-sized nanoparticles (nps) ranging from 
biocompatible silica nps to biodegradable PLGA and PCL nps to adjuvant modular capsomere 
CapM2e using in vivo immunogenicity tests in mice as shown in Chapter 3. Non-significant 
interaction between viral subunit CapM2e and each of the nanoparticles was confirmed by 
determining the extent of absorption of these CapM2e onto these nanoparticles.  
 
Non-adjuvanted CapM2e formulation induced a 104 IgG antibody titer in serum, which was 
consistent with an earlier report [3]. Viral capsomeres possess PAMPs (pathogen-associated 
molecular patterns), which act as danger signals to the immune system by activating the pattern 
recognition receptors on the immune cells [7]. These viral molecular signals of viruses retained in 
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capsomeres may have contributed to high immunogenic stimulation on modularization of weakly 
immunogenic M2e peptide into viral capsomere. 
 
Introduction of nanoparticle in the formulation provides the particle component, which is lacking in 
viral structure of modular capsomeres, thus enhancing their immunogenicity. Formulation of 
CapM2e with silica or PLGA nps by simple-mixing approach significantly boosted the antibody-
biased immunogenicity of these modular capsomeres by more than ten-fold. Despite having similar 
size to silica and PLGA nps, PCL nps did not show any adjuvanting effect. PCL has been shown to 
be more hydrophobic and degrades slower than PLGA [8]. Few studies have reported the effect of 
hydrophobicity of nanoparticles on the immune response induced by formulation of nanoparticles 
with antigen [9, 10]. Therefore, hydrophobic characteristics of PCL might have influenced its 
interaction with either immune system or CapM2e, which consequently would have affected 
antigen processing mechanism. In addition, Yan et. al evaluated the size effect on the adjuvanting 
efficacy of different types of particles and showed that each type of particle had an optimum size 
range for maximum adjuvanting activity [11]. In this study, different nanoparticles were tested 
which had similar size but different physicochemical properties. They showed adjuvanting efficacy 
in this order: silica> PLGA > PCL nps. This could be due to the reason that sizes of PLGA and PCL 
nps were not optimum for their maximum adjuvanting activity.  
 
Silica nps showed the highest adjuvanticity for CapM2e among the tested nanoparticles. Therefore, 
to further study the effect of surface properties on the adjuvanticity of nanoparticles, three different 
variants of silica nanoparticles were tested: negatively-charged unmodified silica nps (Si-OH nps), 
positively-charged amine-functionalized silica nps (Si-NH2 nps) and neutral PEG-functionalized 
silica nps (Si-PEG nps). No significant difference in the M2e-specific antibody titer induced by 
their formulations with CapM2e was observed on varying the surface charge of the nanoparticles. 
This observation could be attributed to the fact that the induced immune response is already at its 
maximum, and therefore no further enhancement of immunogenicity of the formulation could be 
observed on varying the surface properties of the adjuvant particles. 
 
Synergistic effect of non-carrier nanoparticles and capsomeres in the formulation by contributing 
particle and viral molecular signals respectively was observed to result in the induction of maximal 
immune response, thus showing the potential of nanoparticle-augmented capsomere formulation.  
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6.1.2 In vivo trafficking of mixed nanoparticle and modular capsomere vaccine formulation 
Chapter 3 showed the efficacy of silica nps as a non-carrier adjuvant for CapM2e. Non-carrier size-
dependent adjuvanticity of silica particles for CapM2e has been observed previously [12]. While it 
is remarkable that a simple mixed formulation of adjuvant nanoparticles and antigenic modular 
capsomeres exhibits high immunogenicity, an understanding of their biodistribution that results in 
this particular immune response is rather limited. To better understand this effect of biodistribution 
on the immune response, the in vivo trafficking of CapM2e alone and when formulated with non-
carrier silica nano-and micro-sized particles was visualized by NIR fluorescence imaging as 
described in Chapter 4. The corresponding immune response was also analyzed. 
 
After each subcutaneous immunization of vaccine formulations, mice were imaged at two different 
wavelengths at different time points for up to 24 h. The in vivo imaging results showed that the 
majority of CapM2e and adjuvant particles traffic independently from the subcutaneous injection 
site. CapM2e drained into the inguinal lymph nodes while adjuvant particles localized into the 
gastrointestinal tract including stomach and intestines. These observations were supported by ex 
vivo fluorescence analysis of organs excised after euthanizing mice from each group 6 h post third 
immunization. 
 
Non-carrier nanoparticles and CapM2e moved separately from injection site as seen during the in 
vivo imaging, even then the presence of nanoparticles in the formulation boosted the 
immunogenicity of CapM2e formulation. On the other hand, microparticles did not exhibit such 
activity, which highlighted the striking effect of size on the adjuvanting efficacy of silica particles 
and was consistent with a previous study [12]. These observations lead to the hypothesis that 
nanoparticles may be affecting the uptake process of CapM2e at the injection site. CapM2e and 
adjuvant particles seem to remain at the injection site for up to 24 h, although their concentration 
decreased with time. In a somewhat related case, emulsion based adjuvant MF59 has shown a 
similar effective adjuvanting effect despite separate trafficking of antigen and adjuvant in other 
studies [13]. 
 
This study, described in Chapter 4, to the best of my knowledge, is the first to visualize the in vivo 
trafficking of modular capsomeres formulations. The draining of CapM2e into inguinal lymph 
nodes could be responsible for their high immunogenicity, even in the absence of adjuvant, since 
lymph nodes are sites of high concentration of cells of immune system especially, dendritic cells, B 
and T cells [14, 15]. Further, it was observed that microparticles cleared faster than the 
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nanoparticles counterparts, which might have contributed to the size-dependent adjuvanting 
efficacy of silica particles since longer circulation time of adjuvant particles in the body has been 
shown to be favorable for the induction of effective immune response [14]. As discussed in Chapter 
3, silica nps seem to contribute to the immune response by providing particle signals at injection 
site which is deficient in capsomere structure, thus resulting in adjuvanting effect of silica nps even 
though CapM2e and nanoparticles traffic separately in vivo. 
 
6.1.3 Efficacy of sublingually-administered modular VLPs and their in vivo trafficking 
Modular VLPs presenting GAS J8 antigen (J8-VLPs) have demonstrated efficacy by inducing 
systemic opsonizing antibodies in a previous study [2]. In a follow-up study, intranasally-delivered 
J8-VLPs were shown to raise strong antibody response, and conferred protection against lethal 
intranasal challenge [4]. Sublingual delivery is expected to boost both systemic and mucosal 
immunity [16], which is needed for protecting against GAS infections. This study investigated the 
efficacy of sublingually-delivered J8-VLPs using in vivo immunogenicity tests as shown in Chapter 
5. 
 
Sublingual administration of J8-VLPs induced high level of serum IgG and salivary IgA antibodies. 
The serum IgG levels induced by J8-VLPs were comparable after sublingual and subcutaneous 
immunizations, while the salivary IgA levels were significantly higher after sublingual 
immunization as compared to subcutaneously-immunized J8-VLP counterparts. This observation 
showed the advantage of sublingual delivery for providing mucosal immunity, in addition to 
systemic immunity, which is an important criterion for an effective GAS vaccine owing to its 
mucosal nature. 
 
The high immunogenicity of J8-VLPs administered through either route could be due to their 
draining to lymph nodes, visualized through in vivo whole animal fluorescence imaging coupled 
with ex vivo organ imaging, which has been seen for other VLPs in a previous study [17] and for 
VLPs subunit capsomeres in Chapter 4. The imaging showed rapid absorption of J8-VLPs into 
systemic circulation after sublingual immunization and in parallel draining of these J8-VLPs into 
submandibular lymph nodes. On the other hand, J8-VLPs remained at the injection site i.e. near tail 
base after subcutaneous immunization for considerable time (up to 24 h) and drained into lumbar 
and sciatic lymph nodes. To the best of my knowledge, this study is the first report visualizing the 
in vivo trafficking of sublingually-delivered VLPs. 
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Co-administration of mucosal adjuvant cholera toxin (CT) with the sublingually-administered J8-
VLPs significantly boosted their level of salivary IgA antibodies. Serum IgG subclass analysis 
showed that J8-VLPs induced a balanced Th1 and Th2 immune response after sublingual and 
subcutaneous immunization. Co-administration of CT enhanced the levels of IgG1, IgG2a and 
IgG2b induced by the J8-VLP formulation. Murine IgG2a and IgG2b have been shown to be 
associated with the opsonization activity in previous studies [18, 19] and thus may promote 
bacterial clearance. 
 
For a cheaper cold-chain free delivery and storage of GAS vaccine to poor remote developing 
countries which are most affected by GAS diseases, a room temperature stable GAS vaccine is 
highly desirable. The effect of freeze drying on the already established high immunogenicity of 
sublingually-administered J8-VLPs was evaluated in vivo. Freeze-dried formulation of J8-VLPs 
(FD-J8-VLPs), stabilized by sorbitol and polysorbate 20, induced high serum IgG levels, which was 
comparable to non-freeze-dried formulation. Freeze-drying affected the induction of the mucosal 
response as was evident with lower level of salivary IgA antibodies, which however could be 
boosted by employing CT as adjuvant to the level induced by CT-adjuvanted non-freeze-dried 
formulation. 
 
Murine IgA antibodies in saliva raised by immunization with different J8-VLP formulations with 
and without CT were tested for their ability to opsonize GAS in vitro. Among them, J8-VLPs and 
CT-adjuvanted FD-J8-VLPs evoked strong bactericidal antibodies in saliva against GAS reference 
strain. This study demonstrated the potential of sublingually-delivered freeze-dried formulation of 
J8-VLPs as a cost-effective and potent GAS vaccine for delivery to remote poor regions where 
GAS diseases are endemic. 
 
6.2 Future work 
This study demonstrated the efficacy of silica and PLGA nps as non-carrier nanoparticles for 
modular capsomere based influenza vaccine candidate. Fluorescence imaging was employed for 
tracking the movement of vaccine components inside mice after immunization to aid in the 
understanding of their effectiveness in generating specific immune response. Moreover, it 
established the effectiveness of sublingually-administered modular VLP-based GAS vaccine 
candidate, which can be freeze-dried to make it suitable for adoption by poor developing countries. 
These results contribute towards advancing the development of promising vaccine candidates 
targeting these diseases and showed the versatility of this MPyV VP1 based microbial vaccine 
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platform. Designing, production, formulation and efficacy analysis are key areas of vaccine 
development. Further investigation on these areas would foster the development of these vaccine 
candidates:  
I. The clearance profile of nano-and micron-sized silica particles observed in Chapter 4 was 
unexpected, especially fast clearance of microparticles from the injection site within 24 hrs. 
Cell-level analysis of particle uptake via flow cytometry would be beneficial to determine if 
the particles in the different organs are associated with uptake by specific antigen-presenting 
cells (dendritic cells for nanoparticles and macrophages for microparticles respectively) at 
the injection site. Such an analysis in all tissues, particularly lymph node and spleen, would 
provide further information about the role of nanoparticles in improving the antigenicity. 
Moreover, technique such as inductively coupled plasma mass spectrometry (ICP-MS) can 
be used for assessing biodistribution of silica particles at organ level, as done previously 
[20]. In light of the somewhat surprising biodistribution of microparticles, employing such 
complementary technique to confirm these findings will be important. 
II. Preclinical protective efficacy of silica nps-augmented CapM2e formulation has been shown 
in a separate lethal influenza challenge study in mice (unpublished data). The next step to 
advance the development of this vaccine candidate, would be to perform testing on other 
small animal models such as ferrets or large animal models such as non-human primate 
macaques to evaluate its immunogenicity and protective efficacy. 
III. Freeze-drying was observed to reduce the efficacy of sublingually-administered J8-VLPs in 
terms of lower level of induced IgA antibodies in Chapter 5. Such reduced efficacy, even in 
the presence of excipients could be due to either inactivation or aggregation of VLPs or 
lower sublingual delivery efficiency of freeze-dried formulation. To enhance their efficacy, 
freeze-dried formulation of J8-VLPs can be optimized by high-throughput screening of 
different VLP formulations with excipients to improve their biological and physical stability 
[21]. Moreover, dosage of VLPs can be increased to compensate for their reduced activity. 
IV. GAS vaccine development is difficult, confronted with many obstacles such as safety issues 
(potential auto-immune response), absence of human immune correlate of protection against 
GAS infection, various GAS serotypes and antigenic variation within the same serotype [22, 
23]. The lack of complete understanding of immune protection in humans against GAS 
infections has prompted the screening of potential vaccine candidates against surrogate-of-
protection assays and efficacy evaluation in animal challenge models. The functional 
immunological assays (e.g. bactericidal assay) evaluate the biological activity of induced 
antibodies in vitro. Currently used small animal challenge models for assessing the potency 
of GAS vaccines are not fully reliable. This is due to the fact that GAS are mostly human-
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specific pathogens that have adapted with the immune system of the host. These models 
suffer from issues of low sensitivity due to need of high bacterial dose for infection, and 
poor reproducibility [24]. Thus, there is a need for the development of improved immuno-
assays including high throughput bactericidal assays and multiplex enzyme-based assays for 
multiple antigens and their integration into preclinical studies to support the challenge 
models. In this study, sublingually-administered J8-VLPs induced high levels of systemic 
IgG and mucosal IgA antibodies, suggesting their potential protective efficacy. Bactericidal 
assays showed the ability of induced antibodies to opsonize GAS in vitro. This leads to the 
question whether serological and functional assays are sufficient to evaluate the efficacy of a 
vaccine candidate in preclinical settings or is there is a requirement to develop appropriate 
animal models, which are reproducible and reliable. 
V. Based on the success of sublingually-delivered GAS J8 VLPs in inducing systemic as well 
as mucosal immune response, it may be worthwhile to evaluate the sublingual delivery of 
CapM2e. Fluorescence imaging can then be utilized to track the biodistribution, which can 
be correlated with the induced mucosal and systemic immune response, and both vaccines 
can be compared in terms of efficacy. 
VI. As discussed before, one major issue faced during the GAS vaccine development is that 
GAS has many serotypes, which reduces the effectiveness of GAS vaccine candidates, as 
they do not provide protection against different circulating strains in GAS-affected areas. 
Modular VLPs have the potential to be a multivalent vaccine, as it can incorporate multiple-
strain specific antigenic modules, which can provide broad coverage against multiple GAS 
strains and thus can be exploited in future studies. Such a multivalent approach has already 
been effective for human papillomavirus VLP based vaccines against cervical cancer [25]. 
VII. Finally, knowledge obtained from this thesis could be extended to the application of MPyV 
VLP/capsomere platform for other diseases. 
 
6.3 Concluding thoughts 
Developments in the field of molecular biology, immunology and recombinant technology have 
been instrumental in shifting the interest from traditional live and inactivated bacterial and viral 
vaccines to the safer but less immunogenic subunit vaccines. Adjuvants and novel delivery systems 
are explored to enhance the immunogenicity of modern subunit vaccines. Modular VLPs and their 
subunit capsomeres have been used as carrier to present antigenic determinants of pathogens 
different from parent viruses. This thesis highlighted the potential of silica nps-adjuvanted modular 
capsomeres as a cost-effective and potent influenza vaccine which integrates the benefits of 
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capsomeres (cheap, stable, viral molecular structure) and nanoparticles (biocompatible; stable, 
particulate size). It also demonstrated the potential of sublingually-delivered modular VLPs as an 
efficacious GAS vaccine which integrates the benefits of VLPs (stable, cheap, self-adjuvanting, 
amenable to freeze-drying) and sublingual delivery (ease of administration, directing mucosal 
immunity). Furthermore, NIR fluorescence imaging was successfully employed to track the in vivo 
trafficking of the vaccine formulations, which provided an insight into their ability to induce an 
effective immune response. This microbial platform would enable availability of efficacious 
vaccines for rapid response during epidemics and pandemics and at low cost for neglected and 
orphan diseases. 
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